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ABSTRACT 
Hisham S. Aljadhey: The Effects of Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) on Blood Pressure in Patients with Hypertension 
(Under the direction of Michael D. Murray, PharmD, MPH) 
 
Dysregulation of blood pressure control in hypertensive patients using 
nonsteroidal anti-inflammatory drugs (NSAIDs) could increase morbidity, mortality, 
and health care costs. The aims of this research were to examine the association 
between NSAIDs and blood pressure in hypertensive patients, compare the effects 
of various NSAIDs on blood pressure, and determine if NSAIDs were associated 
with changes in antihypertensive therapy.  
This retrospective cohort study included hypertensive patients who received 
their first prescription for any NSAID and met the inclusion criteria. Patients included 
in this research received their care from the medicine practice clinics at Wishard 
Health Services in Indianapolis, Indiana between 1993 and 2006. Patients were 
followed for one year after the first prescription or 30 days after the last prescription 
that was dispensed, whichever was less. Patients meeting the same criteria but who 
were prescribed acetaminophen formed the control group. The primary outcomes 
were first systolic blood pressure and intensification of antihypertensive therapy. 
Covariates affecting blood pressure or the prescribing of NSAIDs were included in 
the statistical models. Propensity score matching techniques were used to balance 
background characteristics between comparison groups.  
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A total of 3,928 eligible patients were prescribed NSAIDs or acetaminophen. 
Compared to acetaminophen, prescription for NSAID was associated with a 2 mmHg 
increase in systolic blood pressure (P = 0.004), and a 6 mmHg increase in those 
concurrently prescribed beta-adrenergic blocker (P = 0.008). Ibuprofen was 
associated with a 3 mmHg increase in systolic blood pressure compared to 
naproxen (P = 0.015), and a 5 mmHg increase compared to celecoxib (P = 0.035). 
Ibuprofen was associated with a higher risk of systolic blood pressure increase of ≥ 
20 mmHg compared to naproxen (odds ratio, 1.57; 95% confidence interval, 1.10 to 
2.25; P = 0.014). Dose effects were not observed for either ibuprofen or naproxen. 
There was no evidence of intensification in antihypertensive therapy in patients 
prescribed NSAIDs.  
In conclusion, NSAIDs were associated with a small increase in systolic blood 
pressure in hypertensive patients compared to acetaminophen. The increase in 
systolic blood pressure from NSAIDs did not increase the risk of intensification of 
antihypertensive treatment. Confirmatory studies will be needed to affirm these 
results.  
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I. INTRODUCTION 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are broadly used for acute 
and chronic conditions including rheumatoid arthritis and osteoarthritis (1-3). 
However, it is widely known that NSAIDs are associated with adverse 
gastrointestinal effects. These adverse effects led to the development of selective 
cyclooxygenase-2 (COX-2) inhibitors in an attempt to provide safer NSAIDs. 
However, concerns have arisen that selective COX-2 inhibitors and non-selective 
NSAIDs cause adverse cardiovascular effects such as myocardial infarction, 
exacerbation of heart failure, and increase in blood pressure (4-8). These concerns 
increased following the withdrawal from the market of two selective COX-2 inhibitors, 
rofecoxib in 2004 and valdecoxib in 2005.  
Blood pressure increase in hypertensive patients can lead to deleterious 
cardiovascular effects. In users of NSAIDs, maintaining or achieving blood pressure 
control would prevent morbidity and mortality and reduce health care costs (9). 
Others have estimated that achieving or maintaining blood pressure control in users 
of selective COX-2 inhibitors would prevent more than 70,000 deaths from stroke 
and 60,000 others from coronary heart disease; such control would also result in 
direct health care cost savings of more than 3.8 billion dollars (9). 
The effect of NSAIDs on blood pressure in patients prescribed 
antihypertensive medications has been investigated in clinical trials, but not in 
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observational studies. These trials have shown that NSAIDs increase blood pressure 
in patients who were using antihypertensive medications including angiotensin-
converting enzyme inhibitors (ACE-I), diuretics, and beta-adrenergic antagonists (10-
16). However, clinical trials are susceptible to selection bias since patients enrolled 
in these trials are different from those in real-world settings (17, 18). In contrast, 
populations included in observational studies are from clinical practice settings. Few 
studies have been published on the effect of NSAIDs on blood pressure in patients 
who are taking more than one antihypertensive medication. This is important since 
more than two-thirds of hypertensive patients require two or more antihypertensive 
medications from different drug classes to control their blood pressure (19).  
The next section starts with a discussion about the significance of NSAID-
induced blood pressure increase, followed by an overview of the main 
characteristics of NSAIDs that may explain how they affect blood pressure. The 
biological mechanisms whereby NSAIDs may cause blood pressure increase are 
discussed. This leads to the specific aims and hypotheses of this research.  
Significance of NSAID-induced Blood Pressure Increase 
Chronic diseases, especially cardiovascular, are the most common cause of 
death in the world (20). In the United States about 73 million people, or one in three 
adults, have high blood pressure. From 1994 to 2004 the death rate from high blood 
pressure increased by 27 percent, and the actual number of deaths rose by 56 
percent (21). Every year, hypertension leads to seven million deaths in the world 
(19). Hypertension is a major cause of cardiovascular diseases and patients are at 
higher risk of myocardial infarction, heart failure, stroke, and kidney disease. For 
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every 20 mmHg systolic or 10 mmHg diastolic increase in blood pressure, the risk of 
mortality doubles for both ischemic heart disease and stroke (19).  
Blood pressure control in hypertensive patients is essential to prevent 
morbidity and mortality, reduce health care utilization, and ultimately lower health 
care costs (9). The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) sets goals for 
patients with hypertension to control blood pressure (19). Blood pressure is only 
controlled in 35% of hypertensive patients (21). It has been estimated that 
inadequate blood pressure control in hypertensive patients results in about 40,000 
cardiovascular events, more than 8,000 cardiovascular deaths, and direct medical 
expenditure of one billion US dollars per year (22, 23). 
Treatment of hypertension is affected by several factors, including 
medications that increase blood pressure. NSAIDs are frequently used for various 
types of pain by hypertensive patients. Even a slight increase in blood pressure 
associated with the use of NSAIDs is considered significant. Decreasing systolic 
blood pressure by just 2 mmHg lowers stroke mortality by 10% and ischemic heart 
disease mortality by 7% (24).   
The effect of NSAIDs on incident hypertension has been investigated in 
previous studies (25-30), but little information is available about the magnitude of 
changes in blood pressure. In 2004, the number of prescriptions for NSAIDs 
exceeded 100 million (31). Few studies have examined the effect of NSAIDs on 
blood pressure in patients who are taking antihypertensive medications. In the 
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United States, more than 20 million patients receive concomitant treatment for 
arthritis and hypertension (31); often NSAIDs are prescribed to relieve symptoms of 
arthritis. The association between NSAIDs and blood pressure increase in patients 
who are taking antihypertensive medications has only been investigated in a meta 
analysis (10) and short-term clinical trials (3, 12-16, 32-43); it has not been the 
subject of observational studies where populations are more broadly relevant to 
most clinical settings. In addition, some of these previous studies did not include the 
more commonly prescribed NSAIDs.  
Previous studies do not indicate whether NSAIDs affect blood pressure in 
patients who are taking multiple antihypertensive medications. This is important 
since most patients are prescribed more than one medication to control their blood 
pressure. In fact, more than two-thirds of hypertensive patients require two or more 
antihypertensive medications from different classes (19). No previous study has 
examined changes to antihypertensive therapy made by prescribers after patients 
started to use NSAIDs.  
Prescribers must first decide whether to prescribe NSAIDs for their 
hypertensive patients, select the NSAID that has the least effect on blood pressure 
regulation, and choose the dose at which the risk of blood pressure dysregulation is 
minimal. The results of this research will help practitioners to control blood pressure 
in hypertensive patients started on NSAIDs. It also will improve health policy 
decisions regarding the management of the risk of blood pressure increase 
associated with NSAIDs.  
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In contrast to previous studies, this research used propensity score matching 
techniques to balance covariates between compared groups (44) and adopted 
incident user design to prevent the inclusion of prevalent user bias (45). This 
research examined the association between NSAIDs and blood pressure in 
hypertensive patients who were prescribed multiple antihypertensive medications. 
Also, it investigated the intensification of antihypertensive therapy by prescribers. 
This research addressed important unanswered questions regarding the use of 
NSAIDs in hypertensive patients. The results of this study will help practitioners to 
select NSAIDs with minimal effect on blood pressure for patients with hypertension.  
Overview of Non-Steroidal Anti-Inflammatory Drugs 
It is important to highlight the characteristics of NSAIDs that are related to 
their effects on blood pressure. This section provides an overview of NSAIDs that 
include indications, differences in pharmacokinetics, main adverse effects, and 
mechanism of action. The most commonly used NSAIDs in practice were included in 
this research, namely ibuprofen (short-acting NSAID), naproxen (long-acting 
NSAID), and celecoxib (the only selective COX-2 inhibitor in the market).  
Indications  
NSAIDs are widely used for chronic conditions including rheumatoid arthritis 
and osteoarthritis. NSAIDs reduce pain, joint swelling and morning stiffness in 
rheumatoid arthritis. NSAIDs are recommended for patients with osteoarthritis as a 
second line treatment, after trying acetaminophen. NSAIDs are also useful for the 
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relief of mild to moderate pain, acute gout, dysmenorrhea, and headache (1-3, 46-
48).   
Pharmacokinetics  
Non-selective NSAIDs are rapidly and completely absorbed. Because they 
are highly bound to proteins, they have small volume of distribution. They are 
metabolized in the liver through cytochrome P450 or by glucuronidation and 
excreted through the kidney as metabolites. The half-life of NSAIDs varies from one 
hour up to 50 hours depending on the agent (1, 49). This variation in half-life could 
explain some of the differences in adverse effects between individual NSAIDs.  
Ibuprofen is well absorbed and peak plasma concentrations are achieved 
within one to two hours after administration. Ibuprofen has short half-life of about 3.5 
hours. This short half-life leads to an intermittent effect during the day. Thus, the 
effect of ibuprofen on blood pressure may not last for a whole day without repeated 
dosing. It is mainly metabolized in the liver, with less than 10 percent excreted 
unchanged in the urine and bile (47).  
Naproxen has a longer half-life of about 13 hours, thus, it suppresses 
prostaglandins (PGs) for a longer period. Therefore, naproxen’s effect on blood 
pressure will presumably be of longer duration. It is well absorbed in the upper 
gastrointestinal tract and is highly bound to plasma proteins. Naproxen is excreted 
entirely in urine as an inactive glucuronide metabolite (47). Clearance of naproxen is 
decreased in patients with renal failure because the acyl-glucuronide metabolite of 
naproxen is retained and hydrolyzed to reform the parent drug (1, 49, 50). This 
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emphasizes the importance of controlling for renal function when studying the 
adverse effects of naproxen.  
Celecoxib has a bioavailability of about 40% and is highly bound to protein, 
mainly to albumin. Because of its lipophilicity, celecoxib has a high volume of 
distribution. The half-life of celecoxib ranges from 11.2 to 15.6 hours. Celecoxib is 
extensively metabolized in the liver through oxidation by cytochrome P450 2C9, and 
less than 2% is excreted unchanged in urine (48, 51).  
Overview of Adverse Effects  
The major adverse effects reported with the use of NSAIDs are 
gastrointestinal, renal, hepatic, cardiovascular, and hematological. Other adverse 
effects which occur less frequently include skin reactions and central nervous 
system reactions such as headache and dizziness.  
The most frequent adverse effects with the use of NSAIDs are 
gastrointestinal. Dyspepsia is the most prevalent, while peptic ulcer and its 
complications are much less common. PGs have an important role in maintaining 
normal gastrointestinal physiology. Inhibition of PGs by NSAIDs could lead to 
gastrointestinal effects that include gastric erosion, peptic ulcer formation and 
perforation, upper gastrointestinal hemorrhage, and inflammation of the intestine and 
lower bowel. One study found that the hazard ratio for hospitalization due to adverse 
gastrointestinal effects in users of NSAIDs is seven times that of patients not treated 
with NSAIDs (49). As a response to these adverse effects, selective COX-2 inhibitors 
were developed. In clinical trials, treatment with selective COX-2 inhibitors causes 
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significantly fewer serious adverse gastrointestinal effects than treatment with 
nonselective NSAIDs (48). 
The risk of adverse cardiovascular effects increases with the use of NSAIDs. 
These effects include myocardial infarction, stroke, heart failure, and increased 
blood pressure (4, 8, 52-57). The use of NSAIDs is associated with various renal 
toxicities, which may lead to acute renal failure and nephropathy (50, 58). Hepatitis 
and liver function abnormalities can occur with the use of NSAIDs. However, clinical 
hepatitis and hepatic death are rare adverse effects. Other rare but dangerous 
adverse hematological effects that could occur include agranulocytosis and aplastic 
anemia (46). 
Mechanism of Action  
NSAIDs have antipyretic, analgesic, and anti-inflammatory properties. The 
major mechanism for their effect is the inhibition of an enzyme called 
cyclooxygenase (COX) (Figure 1). The COX enzyme catalyzes the formation of 
prostanoids (which include PGs, prostacyclins, and thromboxanes) from arachidonic 
acid. When NSAIDs inhibit the COX enzyme, the synthesis of PGs will be stopped 
and inflammation will therefore be reduced.   
NSAIDs vary in their selectivity in inhibiting the two isoforms of the COX 
enzyme, COX-1 and COX-2 (48). Non-selective NSAIDs act by inhibiting both COX-
1 and COX-2. COX-1 is found in most normal cells and tissues, including platelets, 
endothelial cell, cells within the gastrointestinal tract, renal microvasculature, 
glomerulus, and collecting ducts. Inhibition of COX-1 leads to the adverse 
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gastrointestinal effects associated with non-selective NSAIDs. However, COX-2 is 
not expressed in the stomach and is induced during inflammation by cytokines and 
inflammatory mediators. Therefore, compared to the non-selective NSAIDs, selective 
COX-2 inhibitors possess similar pharmacological actions but are associated with a 
lower risk of adverse gastrointestinal effects (48, 52, 53, 59).  
The presence of PGE2 and PGI2 in the kidney could explain some of the 
blood pressure increase associated with NSAIDs. PGE2 is more predominant in the 
interstitial cells and collecting-duct epithelial cells. While PGI2 is predominant in the 
endothelial cells, the thin layer that lines the interior surface of the blood vessels of 
renal arterioles (60). PGE2 decreases sodium reabsorption at the loop of Henle (58). 
PGI2 is a vasodilator and directly stimulates the renin-angiotensin system (58, 60). 
The following section discusses the mechanisms for blood pressure increase 
associated with NSAIDs.   
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Figure 1. NSAIDs General Mechanism of Action  
 
References: (48, 50, 61). NSAIDs: Non-steriodal anti-inflammatory drugs; PG: Prostaglandin. 
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hypotheses that have been put forward to explain the effect of NSAIDs on blood 
pressure control, when these are taken in conjunction with antihypertensive drugs. 
The COX-1 enzyme mediates the production of thromboxane A2. This 
explains the pro-thrombotic effect of NSAIDs. Thromboxane A2 causes platelet 
aggregation, vasoconstriction, and smooth muscle proliferation (Figure 2). These 
effects lead to the formation of a thrombus, resulting in a cardiovascular event. Since 
aspirin inhibits COX-1 in the platelets irreversibly, it is used as a prophylactic of 
thromboembolic disease. However, NSAIDs do not sufficiently inhibit COX-1 to 
suppress the synthesis of thromboxane A2. This explains the lack of cardio-
protective effects of NSAIDs.  
In contrast to COX-1, COX-2 mediates prostacyclin synthesis which causes 
the inhibition of platelet aggregation, vasodilation, and anti-proliferative effects (62). 
The COX-2 enzyme will therefore balance the undesirable effects of COX-1 on 
platelets. Therefore, any NSAID and in particular selective COX-2 inhibitors, by 
shifting the balance toward a pro-thrombotic effect, are expected to be associated 
with an increase in the risk of thrombotic cardiovascular events such as myocardial 
infarction.   
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Figure 2. Mechanism of Adverse Cardiovascular Effects Mediated by Cyclooxygenase Enzyme  
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The biological mechanisms that hypothesized to explain NSAID-induced 
blood pressure increase involve the inhibition of PGs (Figure 3). A direct 
vasoconstriction effect of NSAIDs might be caused by inhibiting the systemic 
vasodilation of PGI2. The inhibition of PGs in the kidney by NSAIDs causes sodium 
and water retention, weight gain, and, ultimately, increases in blood pressure 
through three main pathways. Firstly, inhibition of prostaglandin E2 (PGE2) 
enhances the reabsorption of sodium at the thick ascending loop of Henle in the 
kidney. Secondly, PG inhibition in the kidney causes vasoconstriction in the afferent 
renal arteriole which leads to a decrease in renal blood flow. Thus, reabsorption of 
sodium increases in the proximal tubule. Thirdly, PGs inhibition by NSAIDs 
stimulates the synthesis of a renal peptide called endothelin-1, which causes 
increased sodium and water reabsorption. In addition, renal endothelin-1 raises 
blood pressure through an increase in peripheral vascular resistance (31, 50, 57, 58, 
63-67). 
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Figure 3. Mechanisms of Blood Pressure Increase Associated with NSAIDs  
 
PG: Prostaglandin; ↑: Increase; ↓: Decrease. References: (31, 50, 57, 58, 63-67).  
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(14, 42, 65). Prostacyclin is essential for thiazide diuretics to decrease peripheral 
vascular resistance. NSAIDs interfere with the antihypertensive effect of thiazides by 
inhibiting prostacyclin synthesis (49, 68).  
Inhibition of PGs by NSAIDs explains the loss of blood pressure control 
achieved by beta-adrenergic blockers. PG inhibition by NSAIDs increases sensitivity 
to the vasoconstrictor effects of noradrenaline, angiotensin II, and sympathetic 
nervous system stimulation (68). By blocking beta-receptors the increased sensitivity 
to alpha-adrenergic stimulation caused by NSAIDs increases, resulting in loss of the 
blood pressure lowering effect of beta-adrenergic antagonists (68). Calcium channel 
blockers (CCBs) exert their antihypertensive effect independently of PGs. CCBs 
lower blood pressure by causing a direct vasodilation in the peripheral arteries of the 
vascular smooth muscle. (35, 69).  
Based on the fluid retention mechanism of NSAIDs, it is expected that the 
blood pressure increase associated with NSAIDs is dose dependent. Lower doses of 
these medications may be a reasonable option for some patients with milder forms 
of arthritis. However, no observational study has examined the effect of NSAID dose 
on systolic blood pressure in hypertensive patients. The dose effect of NSAIDs was 
investigated in this study.  
Specific Aims 
This research examines changes in blood pressure after starting patients with 
hypertension on NSAIDs. Previous studies have found a blood pressure increase 
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within a week of starting NSAIDs (3, 11, 13, 40). In hypertensive patients, adequate 
blood pressure control is essential to prevent morbidity and mortality and reduce 
health care costs (9).  
This research addresses important questions that were not answered in 
previous studies regarding the association between blood pressure and NSAIDs in 
hypertensive patients who are taking multiple antihypertensive medications. 
Previous studies that examined the effect of NSAIDs on blood pressure are limited 
and various aspects of this effect remain unclear. For example, although rofecoxib 
was associated with increased blood pressure in previous studies, celecoxib did not 
change blood pressure significantly (2, 3, 15, 29, 40, 43, 70, 71). The effect of 
NSAIDs on incident hypertension has been investigated, but the magnitude of 
changes in blood pressure has not been thoroughly examined. Existing 
observational studies lack the measurement of blood pressure or did not control for 
important confounding variables. Moreover, these studies did not compare the 
effects on blood pressure of non-selective NSAIDs and selective COX-2 inhibitors. 
The effect of NSAIDs on blood pressure in patients using antihypertensive 
medications was investigated in clinical trials only; it has not been studied in 
observational studies, where populations are more similar to those in typical clinical 
settings.  
The first aim of this dissertation was to investigate the effects of NSAIDs on 
blood pressure in hypertensive patients compared to a control group of 
acetaminophen users. CCBs were analyzed separately, since previous studies have 
suggested that the blood pressure increase associated with NSAIDs occur more in 
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patients using any antihypertensive medication except CCB (13, 35, 36, 39). The 
second aim was to compare the effects of ibuprofen and naproxen on blood 
pressure. Ibuprofen has a shorter half-life, leading to an intermittent effect during the 
day; while the half-life of naproxen is longer, leading to continuous PGs suppression. 
Thus, any effect on blood pressure presumably will last longer with naproxen. 
Celecoxib’s effect on blood pressure was compared to that of naproxen and 
ibuprofen. Since celecoxib selectively inhibits COX-2, it might present a different risk 
for blood pressure increase compared to non-selective NSAIDs.  
The specific aims of this study were: (1) to examine the association between 
NSAIDs and blood pressure compared to acetaminophen in patients with 
hypertension; (2) to compare the effects of various NSAIDs on blood pressure in 
patients with hypertension; and (3) to examine changes in antihypertensive therapy 
after starting NSAIDs (Figure 4).  
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Figure 4. Hypotheses by Population, Treatment, and Outcome of the Study  
 
Population  Treatment 
All NSAIDs  
vs.  
Acetaminophen 
Outcome 
Systolic Blood Pressure after 
index date:  
First, average, increases by ≥ 
20 mmHg 
Intensification of 
antihypertensive medications:  
Start new medication or dose 
increase 
Ibuprofen 
vs.  
Naproxen 
Celecoxib 
vs.  
Ibuprofen 
Celecoxib 
vs.  
Naproxen 
All hypertensive  
patients 
Pts. on ACE-I 
Pts. on CCB 
CCB combinations 
with any other 
antihypertensive class 
Pts. on BB 
Pts. on diuretics 
Pts. on two or 
more 
combinations of 
ACE-I, BB, 
diuretics 
*ACE-I: Angiotensin converting enzyme inhibitor; BB: Beta-blocker; CCB: Calcium channel blocker. 
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Aim 1:  To examine the association between NSAIDs and blood pressure 
compared to acetaminophen in patients with hypertension   
Hypothesis H1: Compared to acetaminophen, NSAIDs cause a greater 
increase in systolic blood pressure in patients receiving beta-adrenergic antagonists, 
diuretics, ACE-I, or a combination of these antihypertensive drugs.  
Hypothesis H2: NSAIDs taken in conjunction with CCBs are not associated 
with a greater increase in systolic blood pressure compared to acetaminophen. 
Hypothesis H3: Compared to acetaminophen, NSAIDs are not associated 
with an increase in systolic blood pressure in patients concomitantly receiving CCBs 
with drugs from other antihypertensive classes. 
This aim compared the effect of NSAIDs on blood pressure to a similar control 
group of patients who were prescribed acetaminophen. The effect of NSAIDs on 
blood pressure in patients using antihypertensive medications was examined, as this 
has not been thoroughly investigated in previous studies. The effect of NSAIDs on 
blood pressure in patients using diuretics, ACE-I, angiotensin II antagonists, and 
CCBs was investigated in short-term interventional trials. The results of some of 
these trials were conflicting (3, 12-14, 16, 33-39, 41, 42, 72, 73). No observational 
studies were found that explore the effect of NSAIDs on blood pressure in patients 
taking various antihypertensive medications. In addition, this aim examined the effect 
of NSAIDs on blood pressure in patients prescribed multiple antihypertensive 
medications. No prior study has examined this question.  
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Previous clinical trials show that NSAIDs are not associated with blood 
pressure increase in patients using CCBs (13, 35, 36, 39). This class of 
antihypertensive medications could be an alternative option to control blood 
pressure in patients who need to use NSAID chronically. In this part of the research, 
the effect of NSAIDs on blood pressure was examined in patients who are using 
CCB and those who are using CCB with other combinations.  
Aim 2: To compare the effects of various NSAIDs on blood pressure in 
patients with hypertension 
H1: Ibuprofen, naproxen, and celecoxib do not differ in their propensity to 
increase systolic blood pressure.  
H2: As the dose of ibuprofen or naproxen increases, patient’s systolic blood 
pressure increases.   
H3: In patients taking antihypertensive medications other than CCBs, the use 
of naproxen or ibuprofen is associated with an increase in systolic blood pressure.  
H4: In patients prescribed CCBs, naproxen or ibuprofen is not associated with 
increases in systolic blood pressure. 
H5: In patients concomitantly receiving CCBs and antihypertensives from 
another class, naproxen or ibuprofen is not associated with increases in systolic 
blood pressure. 
 21 
This part of the research compared individual NSAIDs that are commonly 
used in practice with each other. From the non-selective NSAIDs, the focus was on 
comparing ibuprofen to naproxen. The effect of naproxen on blood pressure has not 
been compared to ibuprofen in observational studies. In one short-term 
interventional trial included patients stabilized on hydrocholorothiazide, differences 
between naproxen and ibuprofen were suggested since the mean arterial pressure 
increased with ibuprofen but not with naproxen (12). However, it is unknown if 
naproxen and ibuprofen differ in their effect on blood pressure for patients using 
other antihypertensive medications.  
Previous observational studies have not compared the effect of selective 
COX-2 inhibitors on blood pressure to non-selective NSAIDs. Since celecoxib is the 
only selective COX-2 inhibitor on the market, it was compared to the non-selective 
NSAIDs included in this study. Unlike previous studies, this research explored the 
association between the dose of NSAIDs and blood pressure increase.      
Aim 3: To examine changes in antihypertensive therapy after starting 
NSAIDs  
H1: Compared to acetaminophen, NSAIDs increase the likelihood of adding a 
new antihypertensive medication or increasing the dose of a currently prescribed 
antihypertensive medication.  
H2:  Ibuprofen, naproxen, and celecoxib do not differ in the need to add a 
new antihypertensive medication or increase the dose of the current 
antihypertensive medication.  
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Prescribers should respond to blood pressure increase in patients by 
intensifying antihypertensive therapy. They may increase the dose of the current 
antihypertensive medication or add a new medication from another antihypertensive 
class. Previous studies have not examined whether intensification in 
antihypertensive therapy occurs after patients have been prescribed NSAIDs.  
 
II. REVIEW OF RELATED LITERATURE 
 
Investigators have examined the effects of NSAIDs on blood pressure in both 
healthy and hypertensive patients. Although some studies examined the association 
between blood pressure increase and selective COX-2 inhibitors, most previous 
studies have focused on non-selective NSAIDs. Various designs have been used in 
previous studies. These designs include meta-analyses of published clinical trials, 
short-term interventional trials, and observational studies.  
This chapter discusses those studies that have examined the association 
between NSAIDs and blood pressure increase. It begins with studies that focus on 
the effect of NSAIDs on blood pressure in non-hypertensive individuals. Studies 
involving hypertensive patients will follow. Finally, studies of the effect of NSAIDs on 
blood pressure in patients using specific antihypertensive medications are 
discussed.  
Effect of NSAIDs on Blood Pressure in Non-hypertensive Patients 
Studies have been conducted to examine the effects of non-selective and 
selective COX-2 inhibitors on blood pressure in non-hypertensive individuals. These 
studies include meta-analyses of clinical trials, short-term clinical trials, and 
observational studies. Most observational studies examined the risk of hypertension 
in non-hypertensive subjects.   
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A recent meta-analysis examined the association between selective COX-2 
inhibitors and the risk of hypertension in 19 clinical trials (2). Compared to non-
selective NSAIDs and placebo, the risk of hypertension did not increase significantly 
in users of selective COX-2 inhibitors. However, the results were significant when 
the researchers examined each selective COX-2 inhibitor separately. Rofecoxib was 
associated with a significant increase in the risk of hypertension compared to other 
non-selective NSAIDs (relative risk, 1.78; 95% confidence interval, 1.17 to 2.69) and 
placebo (relative risk, 2.63; 95% confidence interval, 1.42 to 4.85). Nonetheless, 
celecoxib was associated with a non-significant decrease in the risk of hypertension 
as compared to other non-selective NSAIDs (relative risk, 0.82; 95% confidence 
interval, 0.68 to 1.00) and placebo (relative risk, 0.81; 95% confidence interval, 0.13 
to 5.21) (2). The investigators of this meta-analysis appropriately used the Der 
Simonian and Laird method (74) to calculate relative risk within the framework of 
heterogeneous studies. This meta-analysis demonstrates that each selective COX-2 
inhibitor needs to be studied separately, as they may have opposite effects on blood 
pressure. 
Conclusions cannot be drawn from this meta-analysis due to several 
limitations and biases. Most of the blood pressure values were not collected as a 
primary endpoint, and the definition of hypertension may vary among the trials 
included. Further, many of the trials lacked information about pre-existing 
hypertension and the use of antihypertensive medications. Meta-analyses are based 
on clinical trials, where many participant exclusions are applied, and, as such, 
patients in these trials do not represent those in real world practices. 
 25 
To primarily examine the effect of NSAIDs on blood pressure, specific short-
term interventional trials have been conducted. Table (1) summarizes the design, 
sample size and population, drug and dose, duration, and the main results of 
previous short-term interventional trials. Most of these studies show an increase in 
blood pressure with NSAIDs. For example, ibuprofen was associated with an 
increase in blood pressure in a randomized, three-way, crossover study (72). The 
study included ten young subjects, fourteen elderly subjects, and fourteen further 
elderly subjects with renal insufficiency. The subjects were randomized to 800 mg 
ibuprofen three times a day, 20 mg piroxicam, and 200 mg sulindac twice a day. 
Compared to sulindac, ibuprofen increased the systolic blood pressure by 9.7 mmHg 
(P = 0.0002) and diastolic blood pressure by 6.0 mmHg (P = 0.005). In elderly 
subjects with renal insufficiency, the use of ibuprofen was associated with a 
significant increase of 15 mmHg in systolic and 6 mmHg in diastolic blood pressure 
from baseline (72).  
Celecoxib was not associated with an increase in blood pressure in clinical 
trials (75, 76). Twelve young subjects and twelve elderly subjects were randomized 
to celecoxib or diclofenac for two weeks. The change in blood pressure was not 
statistically significant in either group (75). A recent randomized study that included 
24 healthy volunteers found insignificant changes in blood pressure in users of 
rofecoxib, celecoxib, or diclofenac (76).  
Conducting short-term interventional trials is a good approach to the 
investigation of particular adverse effect in controlled conditions. These trials are 
designed to examine the specific adverse effects of medications and compare them 
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to a control group. When they are designed appropriately, and researchers use the 
information on the pharmacokinetics and pharmacodynamics of medications, 
causality can be established between the use of a medication and a particular 
adverse effect. However, these trials include small numbers of patients (usually less 
than 20) and many patients are excluded. In contrast, observational studies include 
patients from real world practices.   
Observational studies have been conducted to assess the association 
between NSAIDs and the risk of hypertension or the frequency of starting 
antihypertensive medications (Table 2). Increased blood pressure was associated 
with the current use of NSAIDs in a cross-sectional community based study (77). 
The researchers interviewed 470 elderly individuals and medication use was 
recorded from the labels of medication containers. The analysis included only the 
use of prescription drugs over the preceding two weeks and non-prescription drugs 
in the past week. Interviewers measured and recorded sitting blood pressure. The 
investigators controlled for age, gender, body mass index, use of antihypertensive 
drugs, and the presence of pain. NSAIDs users had an insignificant 4.86 mmHg 
increase in systolic blood pressure compared to non- NSAIDs users (95% 
confidence interval, − 0.02 to 9.74). However, NSAID users were more likely to have 
systolic blood pressure above 140 mmHg (odds ratio, 2.19; 95% confidence interval, 
1.33 to 3.61) (77). This study is limited in establishing causality since the 
investigators used a cross-sectional design and confounders such as cardiovascular 
and renal diseases were not controlled for in the analysis.  
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Another cross-sectional community-based study found an increase in the 
prescription of antihypertensive medications among 2,805 elderly individuals who 
were using NSAIDs (25). Registered nurses interviewed the subjects, recorded the 
use of medications, and measured blood pressure. Use of medication was 
ascertained by either inspection of drugs’ containers or lists of drugs provided by 
subjects. Blood pressure was calculated as the average of two measurements after 
sitting for 10 minutes. A logistic regression model was used to control for age, 
gender, body mass index, coronary heart disease, smoking, and alcohol use. The 
risk of using antihypertensive medications was 1.4 times higher in those who used 
NSAIDs compared to non-users (95% confidence interval: 1.1 to 1.7). The risk of 
either using antihypertensive medications or untreated high blood pressure was 
higher in NSAID users compared to non-users (odds ratio, 1.2; 95% confidence 
interval, 1.0 to 1.5). However, the use of NSAIDs was not associated with an 
increase in systolic or diastolic blood pressure (25). A confounding bias could have 
affected the results of this study as covariates such as diabetes mellitus and renal 
insufficiency were not included in the analysis. In addition, a cross-sectional study 
cannot establish causality. Therefore the NSAID’s use may not have precipitated the 
diagnosis of hypertension; rather, patients may coincidently have had hypertension 
and started using NSAIDs.   
A case-control study included elderly subjects from the New Jersey Medicaid 
Program who were using NSAIDs (78). The study was conducted to determine 
whether the risk of starting antihypertensive therapy increases in users of NSAIDs. 
Between November 1981 and February 1990, the investigators identified 9,411 
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patients who filled a first prescription for an antihypertensive medication. Drug claims 
were searched for the use of NSAID during the one-year period before the cases. 
The investigators adjusted for age, gender, race, nursing home residence, number of 
prescriptions filled, intensity of physician utilization, and days hospitalized. The odds 
ratio for initiating antihypertensive therapy for recent (less than 60 days) users of 
NSAIDs compared with nonusers was 1.66 (95% confidence interval, 1.54 to 1.80). 
The risk of starting antihypertensive therapy was higher for recent compared to 
former users of NSAIDs (odds ratio, 1.66; 95% confidence interval, 1.54 to 1.80 
versus odds ratio, 1.42; 95% confidence interval, 1.30 to 1.55). Also, the risk 
increased as the daily dose of NSAIDs increased (78). This case-control study did 
not control for important confounders such as pre-existing heart and renal diseases. 
Sub-analyses of large prospective studies show conflicting results on the 
association between NSAIDs and the risk of hypertension. Two large prospective 
analyses from the Nurses’ Health Study found a significant increase in the risk of 
hypertension diagnosis among women using NSAIDs and acetaminophen. Bias 
could be introduced in these studies since self-report was used to ascertain 
hypertension diagnosis and NSAID use (26, 27). In a prospective study of 8,229 
male physicians followed for a mean of 5.8 years, NSAID use did not significantly 
increase the risk of hypertension (28). Again, self-report was used to ascertain 
exposure to NSAIDs. The study outcome was self-reported blood pressure of 140/90 
mmHg or higher or the use of antihypertensive medication (28). It is unclear whether 
these conflicting results are because of gender differences or because of limitations 
in study design. In these studies, the investigators collectively analyzed all NSAIDs. 
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However, various NSAIDs may differ in their effects on blood pressure. Since self-
report was used to ascertain both exposure and outcome, misclassification bias is a 
major threat to these results.  
A recent case-control study found an increase in the risk of hypertension 
diagnosis in users of rofecoxib, but not celecoxib (29). The study included 3,915 
cases of newly diagnosed hypertensive patients aged ≥ 65 years. Exposure to 
selective COX-2 inhibitors was ascertained during the previous 90 days. A backward 
selection procedure was used to build a multiple logistic regression model. The 
investigators adjusted for age, gender, race, hospitalization, number of ambulatory 
care visits, number of comorbidities, glucocorticoids use, coronary artery disease, 
diabetes, rheumatoid arthritis, and osteoarthritis. Compared to celecoxib, the odds 
ratio of developing hypertension in the rofecoxib group was 1.6 (95% confidence 
interval, 1.2 to 2.1). Compared to non-selective NSAIDs, the risk of hypertension 
increased significantly in users of rofecoxib (odds ratio, 1.4; 95% confidence interval, 
1.1 to 1.9). Compared to celecoxib, the risk of hypertension associated with 
rofecoxib increased in patients with congestive heart failure, liver disease, or renal 
disease (odds ratio, 2.1; 95% confidence interval, 1.0 to 4.3) (29). The results of this 
study revealed that celecoxib is not associated with an increased risk of 
hypertension. However, modest increases in blood pressure may take a longer time 
to result in the diagnosis of hypertension. Since investigators of this case-control 
study ascertained exposure to selective COX-2 inhibitors for only 90 days, they 
could have missed a modest increase in blood pressure associated with celecoxib. 
In contrast, the current study was designed to detect small blood pressure increases 
 30 
with NSAIDs by using systolic blood pressure measurements as the dependent 
variable.   
A recent study examined the effects of switching patients from celecoxib to 
rofecoxib on the blood pressure of 120 Native American patients (79). The 
investigators gathered clinical data, including blood pressure, from medical records. 
Using simple paired t-tests, blood pressure increased when patients switched from 
celecoxib to rofecoxib (systolic blood pressure increased by 2.9 mmHg, and diastolic 
blood pressure increased by 1.5 mmHg). This study did not control for covariates 
likely to affect blood pressure such as changes in antihypertensive medications (79). 
The above-mentioned studies show that the risk of hypertension increases in 
non-hypertensive individuals who are prescribed non-selective NSAIDs or rofecoxib. 
However, celecoxib was not associated with an increase in the risk of hypertension. 
The next obvious research question is how NSAIDs affect blood pressure control in 
patients who already have hypertension. The following section discusses studies 
that investigate the effect of NSAIDs on blood pressure in hypertensives. 
Effect of NSAIDs on Blood Pressure in Hypertensive Patients 
In a meta-analysis published in 1993, blood pressure increased in users of 
indomethacin and naproxen but not in users of other non-selective NSAIDs (57). The 
authors excluded studies where 20% or more of the participants dropped out and 
those where antihypertensive treatment was adjusted while patients were taking 
NSAIDs. Fifty-four clinical trials were included wherein approximately 50% of the 
patients were taking indomethacin and 92% of them were hypertensive. The results 
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indicated a significant increase in mean arterial pressure (MAP) in hypertensive 
patients only, with an increase of 3 mmHg in indomethacin and naproxen users (P 
<0.001). Ibuprofen, piroxicam, and sulindac did not significantly increase blood 
pressure (57). Since the average age of patients was 46 years (subjects ranged from 
28 to 62 years) and patients with severe hypertension were excluded, the results of 
this meta-analysis can be generalized to only healthier younger patients. As older 
patients and those with severe hypertension were excluded, this meta-analysis is 
likely to have underestimated the effect of NSAIDs on blood pressure.  
In short-term interventional clinical trials of hypertensive patients, blood 
pressure increased with the use of rofecoxib but not with celecoxib (3, 43). In a 
randomized double-blind clinical trial, 810 hypertensive elderly patients with 
osteoarthritis were randomized to rofecoxib or celecoxib (3). The investigators 
excluded patients with renal disease, hepatic diseases, or congestive heart failure. 
The change from baseline in mean systolic blood pressure was significantly greater 
for rofecoxib (+ 2.6 mmHg) compared to celecoxib (– 0.5 mmHg) (P = 0.007) (3). A 
recent randomized double-blind twelve-week trial included 404 patients with 
osteoarthritis, hypertension, and diabetes mellitus. Patients were randomized to 
rofecoxib 25 mg, celecoxib 200 mg, or naproxen 1000 mg daily. Blood pressure 
increased significantly in the rofecoxib group only, where the systolic pressure 
increased by 4 mmHg and the diastolic increased by 2 mmHg (P <0.01) (43).  
Only two observational studies have examined the effect of NSAIDs on blood 
pressure in hypertensive patients (70, 71). A small retrospective review of medical 
records included 109 patients who received a new prescription claim for celecoxib or 
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rofecoxib (70). The investigators included blood pressure values that were available 
within 90 days before and after the prescription of selective COX-2 inhibitors. They 
adjusted for age, race, hypertension, number of hypertension medications, 
cardiovascular disease, hyperlipidemia, and dose of selective COX-2 inhibitor. 
Systolic blood pressure increased by 5 mmHg after the start of treatment with 
rofecoxib (P = 0.044). In those 65 years of age and older, systolic blood pressure 
increased in the rofecoxib group by 7 mmHg (P = 0.02). However, celecoxib use was 
associated with a non-significant decrease in blood pressure of 1 mmHg (95% 
confidence interval, − 6.19 to 3.87) (70).  
Another retrospective study used electronic medical records to examine the 
effects of selective COX-2 inhibitors on blood pressure in hypertensive patients (71). 
The investigators included 960 hypertensive patients older than 55 years, who had 
received a stable antihypertensive medication dose four months before COX-2 
prescription. Patients were followed for 6 months. Patients with a history of heart 
failure were excluded. The analysis controlled for age, sex, number of comorbid 
conditions, and number of antihypertensive medications. The use of rofecoxib or 
celecoxib did not affect the blood pressure or the rate of adding another class of 
antihypertensive medications. However, this study might have missed moderate 
changes in blood pressure since the primary outcome was defined as systolic blood 
pressure increase by more than 20 mmHg, or diastolic pressure by more than 15 
mmHg. Compared to celecoxib, the dose of antihypertensive medications increased 
in rofecoxib users (odds ratio, 1.68; 95% confidence interval, 1.09 to 2.60). Patients 
who had changes in antihypertensive therapy were included in this study. These 
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changes could diminish the effect of selective COX-2 inhibitors on blood pressure. In 
addition, this study did not control for some covariates likely to affect blood pressure. 
The effect of selective COX-2 inhibitors on blood pressure was not examined by type 
of antihypertensive medication (71).  
In these abovementioned studies, the use of some NSAIDs was associated 
with blood pressure increase in hypertensive patients. However, analyses did not 
control for the use of antihypertensive medications. Also, investigators did not 
examine the specific antihypertensive type. This is important, as the effect of 
NSAIDs on blood pressure may vary based on the antihypertensive class. The 
following section discusses studies that included hypertensive patients who were 
using specific antihypertensive medications.  
Effect of NSAIDs on Blood Pressure in Hypertensive Patients by Type of 
Antihypertensive Medication 
Meta-analysis and clinical trials have examined the effects of non-selective 
and selective COX-2 inhibitors on blood pressure in hypertensive patients using 
specific types of antihypertensive medications such as ACE-I, angiotensin II receptor 
antagonists, CCBs, diuretics, and beta-adrenergic antagonists. No observational 
studies were found that examined the association between NSAIDs and blood 
pressure increase in hypertensive patients who used any of these antihypertensive 
medications.  
In a meta-analysis of 50 clinical trials examining the effect of NSAIDs on 
blood pressure, patients who were controlled on beta-adrenergic antagonists had a 
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significant blood pressure increase (10). Two of the authors independently reviewed 
each identified trial and decided whether to include it in the meta-analysis. Overall, 
the use of any non-selective NSAID increased the mean blood pressure by 5 mmHg 
(95% confidence interval, 1.2 to 8.7). However, NSAIDs did not significantly alter 
body weight, daily urinary sodium output, creatinine clearance, plasma renin activity, 
or 24-hour urinary PG E2. Only the use of piroxicam was associated with a 
significant increase in the mean blood pressure of 6.2 mmHg (95% confidence 
interval, 0.8 to 11.5 mmHg). In contrast, no changes in blood pressure were 
observed with the use of ibuprofen or naproxen. Analysis was also performed 
according to the use of antihypertensives. Patients who were prescribed beta-
adrenergic antagonists had a significant increase in blood pressure after using any 
non-selective NSAID (blood pressure increase, 6.2 mmHg; 95% confidence interval, 
1.1 to 11.4 mmHg). There was no significant increase in blood pressure in patients 
prescribed diuretics or vasodilators (10).   
Several short-term clinical trials have investigated the effect of NSAIDs on 
blood pressure in patients who were taking antihypertensive medications. Ibuprofen 
use for three weeks was associated with a significant blood pressure increase in 45 
subjects who were taking at least two antihypertensive medications (32). Systolic 
blood pressure increased in the ibuprofen group by 6.8 mmHg, compared to a 
reduction by 3.7 mmHg in the placebo group (P = 0.02). Also, diastolic blood 
pressure increased by 5.3 mmHg in users of ibuprofen compared to a reduction by 
1.1 mmHg in the placebo group (P = 0.03) (32). However, this study did not examine 
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sub-samples of patients who were prescribed various combinations of 
antihypertensive medications.  
A one week trial showed that blood pressure increased in users of ACE-I but 
not in users of CCBs (13). This randomized-crossover study included 18 patients 
who responded to four-weeks of treatment with enalapril or nifedipine defined as 
diastolic blood pressure <90 mmHg or a fall of >10 mmHg from baseline diastolic 
blood pressure. Patients were started on aspirin (100 mg/day for 2 weeks) followed 
by indomethacin (75 mg/day for 1 week). Indomethacin increased blood pressure 
significantly only in the enalapril group (6.8 mmHg increase in systolic blood 
pressure and 4.6 mmHg increase in diastolic blood pressure) (P <0.01). Since 
indomethacin reduced the fractional excretion of sodium in both the enalapril and 
nifedipine groups and blood pressure only increased in the enalapril group, the 
mechanism of blood pressure increase is not due to decreased renal sodium 
excretion. Rather, it is presumably due to inhibition of vasodilatory PG production 
induced by ACE inhibitors (13).  
Another study was conducted to investigate the effects of rofecoxib on blood 
pressure (15). The investigators included twenty hypertensive patients who had 
stable blood pressure with ACE-I and beta-blockers. Rofecoxib was not associated 
with an increase in day-time blood pressure, but night-time systolic blood pressure 
increased by 15.7 mmHg, and diastolic by 8.5 mmHg (P <0.05) (15). Another 
randomized multi-center trial involved 385 patients who were stable on ACE-I for one 
month. Patients were randomized to ibuprofen, celecoxib, nabumetone, or a 
placebo. Systolic and diastolic blood pressure increased significantly only in the 
 36 
ibuprofen group as compared to the placebo group (P <0.01) (42). However, 
celecoxib and diclofenac were associated with a 4 mmHg increase in systolic blood 
pressure in osteoarthritis patients who were treated with ACE-I (P <0.005) (16). 
In 178 hypertensive patients whose blood pressure was controlled by 
lisinopril, the use of celecoxib 400 mg daily did not significantly affect blood pressure 
(41). This result is consistent with previous studies examining the effect of celecoxib 
on blood pressure (3, 43, 70, 71). In a six-week trial, mean systolic blood pressure 
increased significantly in users of rofecoxib (+ 3 mmHg) compared to users of 
celecoxib (-0.4 mmHg) (P <0.001). Systolic blood pressure increase was greater in 
users of rofecoxib, who were controlled on ACE-I and beta blockers (approximately 5 
mmHg) (P ≤0.04). However, changes in systolic blood pressure were not statistically 
significant in those controlled on CCBs or diuretics (40). The results of this study 
support the hypothesis that destabilization of blood pressure depends on the type of 
antihypertensive medication.  
It is unclear if NSAIDs destabilize blood pressure in users of angiotensin II 
receptor antagonists. In a small clinical trial that included 10 hypertensive patients 
who were controlled on losartan, the use of indomethacin for one week did not affect 
blood pressure (38). In contrast, in a larger study of 128 hypertensive patients who 
were controlled on valsartan or lisinopril, indomethacin increased systolic and 
diastolic blood pressures significantly by 5.45 mmHg and 3.22 mmHg in users of 
lisinopril, and by 2.12 mmHg and 1.87 mmHg in users of valsartan (P = 0.01) (14). 
Changes in blood pressure were not significantly different between the valsartan and 
lisinopril groups (P = 0.34) (14).  
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In previous clinical trials, the blood pressure lowering effect of CCBs was not 
affected by NSAIDs (13, 35, 36, 39). A randomized multi-center double-blind study 
included 162 hypertensive patients who had their blood pressure controlled with 
verapamil. Neither ibuprofen nor naproxen significantly affected blood pressure (35). 
The use of naproxen for four weeks did not change blood pressure significantly in 
100 patients who had their blood pressure controlled with nicardipine, a calcium 
channel blocker (36). Another double-blind crossover study included 61 hypertensive 
patients who were controlled on amlodipine or enalapril. The use of indomethacin 
was associated with a 10 mmHg increase in systolic blood pressure when compared 
to placebo. This increase was observed only in the enalapril group. Diastolic blood 
pressure did not increase significantly in either group (39). In another trial, 
indomethacin did not affect blood pressure in users of CCBs (13).  
Related literature shows conflicting results on the destabilization of blood 
pressure associated with the use of NSAIDs in patients on diuretics (12, 33, 34, 37). 
In two randomized clinical trials, the addition of ibuprofen did not affect blood 
pressure control in patients receiving thiazide diuretics alone (33, 34). However, 
another double-blind, randomized, multi-center clinical trial included 97 hypertensive 
patients who were taking hydochlorothiazide (12). Subjects were randomized to 
either ibuprofen or naproxen. Ibuprofen use was associated with an increase in 
diastolic blood pressure by 2.6 mmHg (P = 0.004) and mean arterial pressure by 2.7 
mmHg (P = 0.019). Naproxen was associated only with an increase in diastolic blood 
pressure by 1.8 mmHg (P = 0.043) (12). Another randomized double-blind, 
crossover study involved 22 elderly patients whose hypertension was controlled on 
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hydrochlorothiazide. Systolic blood pressure increased significantly by about 4 
mmHg in the ibuprofen group as compared to the placebo group. No significant 
changes in diastolic blood pressure occurred (37). 
These above studies examined the effect of NSAIDs on blood pressure 
stabilization in patients who were controlled on one antihypertensive class of 
medication. However, no study has examined the effect of NSAIDs in patients who 
are taking more than one antihypertensive medication. This is important since more 
than two-thirds of hypertensive patients require two or more antihypertensive 
medications from different drug classes to control their blood pressure (19).  
Summary 
Previous studies have examined the association between NSAIDs and blood 
pressure increase in non-hypertensive individuals, hypertensive patients, and 
patients who were prescribed specific antihypertensive medications. Overall, non-
selective NSAIDs have been found to be associated with blood pressure increase in 
both normotensive and hypertensive patients. In observational studies, NSAIDs were 
associated with an increased risk of hypertension. Risk factors included age, renal 
insufficiency, congestive heart failure, and liver and renal diseases. Previous studies 
have shown conflicting results regarding the effect of selective COX-2 inhibitors on 
blood pressure. While, in most studies, rofecoxib was associated with an increase in 
blood pressure, celecoxib was not. NSAIDs increased blood pressure in users of 
ACE-I and angiotensin II antagonists. However, it is unclear whether NSAIDs affect 
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the blood pressure in users of beta-adrenergic antagonists or diuretics. Clinical trials 
have shown that NSAIDs do not attenuate the antihypertensive effect of CCBs.  
Several research questions have not been answered by previous studies. The 
effect of NSAIDs on incident hypertension has been investigated, but the magnitude 
of change in blood pressure was not thoroughly examined. Observational studies did 
not compare the effect on blood pressure of individual NSAIDs. This comparison is 
important since some NSAIDs may lack such effect and be useful for patients with 
hypertension. Previous observational studies have not studied the effect of NSAIDs 
on blood pressure in patients using various antihypertensive medications. The dose-
effect of NSAIDs was not examined in previous observational studies. Nor did 
previous studies examine changes in antihypertensive therapy after starting NSAIDs.  
Designs used in previous studies included meta-analyses of published clinical 
trials, short-term interventional trials, and observational studies. The limitations of 
meta-analyses include combining heterogeneous clinical trials and excluding 
patients with comorbidities. Short-term interventional trials provide useful information 
on the association between medications and adverse effects. However, these trials 
include small numbers of patients (usually less than 20) and many patients are 
excluded.  
Compared to meta-analyses and short-term trials, observational studies 
include patients from real world practices. However, previous observational studies 
have been limited in that some were cross-sectional and others did not control for 
key confounders. In contrast, the current study design avoided several biases and 
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controlled for known confounders using the propensity score method to balance 
covariates between the compared groups.  
Conceptual Framework 
Overview 
A conceptual framework was created to demonstrate the relationship between 
the use of NSAIDs, blood pressure increase, and changes in antihypertensive 
therapy (Figure 5). Several factors could affect the exposure to NSAIDs and the 
outcomes of interest in this study. Controlling for these factors in the analysis is 
important. Patients are prescribed NSAIDs according to their individual 
characteristics. For example, the presence of comorbidities could influence the 
prescribing of selective COX-2 inhibitors rather than non-selective NSAIDs. 
Numerous covariates increase blood pressure. An increase in blood pressure could 
influence the physician’s decisions to intensify antihypertensive therapy. This section 
discusses confounders that affect exposure to NSAIDs or blood pressure. These 
confounders are classified into demographics, comorbidities, health status, and the 
use of, and adherence to, antihypertensive medications.  
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Figure 5. Conceptual Model 
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Demographics 
Studies need to control for demographic covariates such as race, age, and 
gender when examining the effect of medications on blood pressure. Prevalence 
and severity of hypertension varies across race in the US population. For example, 
hypertension is more severe in the African-American than in the white population 
(19). Age is a risk factor for hypertension and other cardiovascular diseases. Data 
from previous studies show that older adults are at higher risk of developing 
hypertension (19). Indeed, the prevalence of hypertension increases in over 60-year-
olds to more than fifty percent (19). Several changes in vascular and cardiac 
physiology due to aging lead to hypertension, congestive heart failure, 
atherosclerosis, and stroke (80, 81). The increased risk of hypertension with aging is 
presumably an increase in systolic blood pressure (19). In addition to the increased 
risk of hypertension, the elderly suffer from multiple chronic conditions, such as 
rheumatoid arthritis and osteoarthritis, and thus they are prescribed NSAIDs more 
frequently (82, 83).  
Older adults also are more prone to adverse drug effects because of changes 
in the pharmacokinetics and pharmacodynamics of medications. For many drugs, 
metabolism and excretion of medications slow in the elderly since kidney and liver 
functions diminish with aging. This causes greater exposure to medications and can 
increase the risk of developing adverse effects (84, 85).  
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Comorbidities 
1. Renal insufficiency  
Renal insufficiency augments the risk of blood pressure increase. Prescribing 
selective COX-2 inhibitors increases in patients with renal insufficiency (86). It was 
found that selective COX-2 inhibitors are 2.5 times more likely to be used by patients 
with renal insufficiency (86). Since sicker patients, including patients with renal 
insufficiency, are at a higher risk of gastrointestinal effects, they are often prescribed 
selective COX-2 inhibitors.  
2. Cirrhosis with ascites 
Deterioration of renal function associated with cirrhosis may increase blood 
pressure. Renal synthesis of PGs increases in patients with cirrhosis and ascites. 
Thus, inhibition of PGs by NSAIDs results in deterioration of renal function because 
PGs are essential in maintaining both glomerular filtration rate (GFR) and sodium 
and water excretion. In patients with hepatic cirrhosis and ascites, the use of 
NSAIDs was associated with a 50% reduction in GFR and a 42% reduction in 
sodium excretion (50, 87). However, GFR did not change significantly in cirrhotic 
patients without ascites (87). The number of patients with cirrhosis and ascites is 
small in the general population and in the database used for the present study, but it 
is important to consider this disorder in the analysis.   
3. Systemic lupus erythematosus 
Deterioration of renal function associated with systemic lupus erythematosus 
may increase blood pressure. The basal renal PG synthesis decreases in systemic 
lupus erythematosus. Thus, the inhibition of PGs by NSAIDs increases the risk of 
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renal toxicities in patients with lupus. In one study, the use of NSAIDs in patients with 
systemic lupus erythematosus was associated with a 60% reduction in GFR (87). 
Therefore, patients with lupus are at a higher risk for NSAIDs’ adverse renal effect, 
which may result in blood pressure increase. Again, the number of patients with 
lupus is small.  
4. Rheumatoid arthritis and osteoarthritis 
NSAIDs are prescribed for the pain and inflammation associated with 
rheumatoid arthritis and osteoarthritis. Rheumatoid arthritis (RA) affects 1% of the 
adult population in the US (88). RA is an autoimmune disorder that may result in 
progressive joint destruction, deformity, and disability. Patients with RA suffer from 
pain, stiffness, swelling, and limitation in the motion of multiple joints (89). According 
to the American College of Rheumatology guidelines, NSAIDs are considered one of 
the first line treatments for RA (88).  
Osteoarthritis (OA) affects more people than RA. It has been estimated that 
about 12% of Americans aged 25 and older suffer from symptoms of OA (90). OA 
causes pain and swelling of joints in the fingers, hips, knees, feet, and spine (91). 
Relief of moderate joint pain in patients with OA can be achieved with 
acetaminophen as effectively as with NSAIDs (92). 
5. Diabetes mellitus  
Diabetes is a major risk factor for cardiovascular diseases, including 
hypertension. Blood pressure increase is common in patients with diabetes mellitus. 
In addition, patients with diabetes are at a higher risk of the blood pressure increase 
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associated with NSAIDs (19). Treatment of hypertension should be intensified in 
diabetic patients, to prevent morbidity and mortality (93). The target of blood 
pressure control for hypertensive patients is to achieve a systolic blood pressure less 
than 140 mmHg and diastolic less than 90 mmHg. However, for patients with 
diabetes or renal disease the target is stricter, to levels of less than 130 mmHg 
systolic blood pressure and less than 80 mmHg diastolic. Hence, most diabetic 
patients will be on two or more antihypertensive medications to achieve this level of 
blood pressure control (19, 93).  
Health Status  
When studying the effect of NSAIDs on blood pressure, controlling for health 
status could prevent bias resulting from a comparison to healthier or sicker patients. 
Several studies indicate that sicker patients are prescribed selective COX-2 
inhibitors to avoid the gastrointestinal effects associated with non-selective NSAIDs 
(94-97). An observational study conducted in France included 46,581 patients and 
found that more users of selective COX-2 inhibitors had gastrointestinal and 
cardiovascular histories (95). Two studies in the Netherlands have shown that users 
of selective COX-2 inhibitors were more likely to have cardiovascular comorbidities 
(96, 97). Another study compared the use of non-selective NSAIDs and selective 
COX-2 inhibitors between the US and UK populations. In both countries, more users 
of selective COX-2 inhibitors compared to NSAIDs had cardiovascular and other 
chronic diseases (94). Therefore, channeling bias is a major threat to the validity of 
any study that compares non-selective NSAIDs to selective COX-2 inhibitors. 
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Channeling bias occurs when certain medications are prescribed to patients with 
major prognostic differences (98).  
The Use of Antihypertensive Medications 
The use of antihypertensive medications confounds the association between 
NSAIDs and blood pressure. Patients with hypertension are often started on lifestyle 
modifications that include diet and exercise to control their blood pressure. When 
these lifestyle modifications are insufficient to control blood pressure, or if the patient 
fails to implement them properly, the physician will usually start antihypertensive 
medications.  
JNC 7 recommends starting patients with stage two hypertension (systolic 
blood pressure of ≥160, or diastolic blood pressure of ≥100) on two antihypertensive 
medications (19). However, physicians may start patients on a single drug. Then, 
after maximizing the dose, they may add a second medication from another class to 
control blood pressure.  
Current hypertension guidelines recommend starting patients on thiazide 
diuretics because they are associated with better clinical outcomes and less 
mortality than other antihypertensive medications (19). In addition, diuretics are less 
expensive than other antihypertensive medications. However, the choice of which 
antihypertensive medication to start depends on several factors. These factors 
include compelling indications, cost, and patient factors. Patients with compelling 
indications may start on a different class of antihypertensive medications. For 
instance, ACE-I might be started in patients diagnosed with both hypertension and 
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diabetes mellitus. In addition to lowering blood pressure, ACE-I protects renal 
function (93). After starting any of the antihypertensive medications, the blood 
pressure response could vary between patients depending on the class used and 
whether the patient is taking it as prescribed.  
Adherence to Antihypertensive Medications 
Adherence to antihypertensive medications directly affects blood pressure 
(99). Adherent patients should have better blood pressure control than those who 
are non-adherent. In addition, controlling for adherence could work as a proxy for 
other unmeasured factors, such as adherence to lifestyle modifications and 
socioeconomic factors. Therefore, adherence to antihypertensive medications needs 
to be controlled for in the analysis. 
It is important to include the above-mentioned covariates in the model when 
studying the association between NSAIDs and blood pressure. One of the 
advantages of the source database used in this research is the availability of all 
these clinical factors, enabling them to be controlled in the analysis. The next 
chapter discusses the subjects included in this research and the methods employed.  
 
III. RESEARCH DESIGN AND METHODS  
Subjects 
This research required an appropriate database that contains accurate and 
complete clinical information. Although several large claim databases exist, they 
have limitations that make them unsuitable for addressing certain clinical questions. 
Since many databases have been constructed for non-clinical purposes, the validity 
of the clinical information, especially diagnosis, is uncertain (100). The main 
objective of the current study was to examine the magnitude of changes in systolic 
blood pressure. Claim databases do not collect blood pressure measurements. In 
contrast, the Regenstrief Medical Record System (RMRS) database contains clinical 
data including blood pressure measurements that have been collected for clinical 
purposes.  
Patients included in this research received their treatment from a large inner-
city medicine practice in Indianapolis, Indiana. RMRS was used to identify eligible 
patients and collect data on relevant variables. The RMRS is an electronic medical 
record system that captures patient data from hospitals and outpatient medical 
practices at the Indiana University Medical Center and from 30 practices in inner-city 
Indianapolis (101). The RMRS captures prescriptions, laboratory, and other clinical 
data (101).  
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The index date was defined as the date of the first NSAID or acetaminophen 
prescription. The index drug is the NSAID or acetaminophen that was initiated at the 
index date. The baseline is the time within a year before the index date. Post-index 
is the time after the index date and before the end date. The study was approved by 
the Institution Review Boards at the University of North Carolina at Chapel Hill and 
Indiana University-Purdue University at Indianapolis. 
Patients were included in this research if they had received a prescription for 
any NSAID, were aged 18 years or older, and had a clinical diagnosis of 
hypertension at baseline. Patients could not have had an active prescription for any 
NSAID during the year preceding the index date. Included patients must have had at 
least one sitting systolic blood pressure measurement at baseline. Because these 
medications could increase blood pressure, patients using cyclosporine, tacrolimus, 
cisplatin, or carboplatin were excluded.  
For the first two aims of this study that examine the association between 
NSAIDs and systolic blood pressure, included patients must have had at least one 
post-index measurement of sitting systolic blood pressure. Patients were required to 
have received the same index drug and had stable antihypertensive therapy until the 
measurement of blood pressure. Patients were therefore excluded if their 
antihypertensive therapy had changed, either by increasing the dose or changing 
antihypertensive medications. Patients meeting the same criteria but who had been 
prescribed acetaminophen formed the control group. 
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For the third aim that examines the association between NSAIDs and 
changes in antihypertensive therapy, the same aforementioned inclusion criteria 
were used except that patients were not required to have had post-index blood 
pressure measurement and patients who had changes in antihypertensive therapy 
were not excluded.  
Possible Endogeneity of Changes in Antihypertensive Therapy 
Controlling for changes in antihypertensive therapy in the regression analysis 
is an option when studying the association between NSAIDs and blood pressure. 
However, the inclusion of changes in antihypertensive therapy in the model as an 
independent variable may present a problem of endogeneity. Endogeneity occurs 
when the effect of one independent variable is predicted by other independent 
variables in the same model. The endogenous variable is correlated with the error 
term and results in a biased estimate. In this study, changes in antihypertensive 
therapy were determined by other variables that should be included in the main 
model.  
One option to handle the endogeneity problem is to include an instrumental 
variable in the model. An instrumental variable is one that is related to the 
endogenous variable but at the same time is not related to the outcome of interest. 
In this case, it should be related to the changes in the antihypertensive therapy but 
not directly related to blood pressure. However, it is difficult to find a variable within 
this database that exhibits these characteristics. Another way to handle endogeneity 
is to exclude endogenous variables. This results in an unbiased estimate, but the 
coefficient on NSAIDs includes the effect of changes in therapy as well as the effect 
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of NSAIDs used. Therefore, caution is required when interpreting the results. A better 
option is excluding patients who have had changes in antihypertensive therapy. In 
this study, the latter option was adopted to provide the least biased estimate.  
Design  
A retrospective design was used to include incident users of NSAIDs (Figure 
6). Incident users are those patients who started the medication for the first time 
after a specific period of non-use. In contrast, prevalent users are those patients who 
have been taking the drug prior to entry into the study. The inclusion of prevalent 
users can introduce two types of bias: 1) under-ascertainment of adverse effects that 
occur early in treatment and 2) the inability to control for some risk factors that may 
be altered by the study drugs. When the risk of adverse effects is higher at the 
beginning of drug treatment, the inclusion of prevalent users will underestimate the 
risk associated with the drug (45). Prior research indicates that blood pressure may 
increase within a few days after starting NSAIDs. Therefore, studying the effects of 
NSAIDs on blood pressure is vulnerable to this bias, as patients may stop NSAIDs 
once they experience adverse effects.  
The other bias from including prevalent users is the inability to control for 
confounders that were affected by the treatment itself. Since NSAIDs affect 
covariates such as baseline blood pressure and the use of antihypertensive 
medications, controlling for these covariates will be incomplete in prevalent users 
leading to a biased estimate.  
 
 52 
Figure 6. Comparison between Incident User and Prevalent User Designs  
 
Subject A: In the incident user design all patients will be included and covariates were 
collected before the drug started. Subject B: Covariates collected at the start of the study 
might be affected by the drug. Subject C: Subjects who stopped the drug because of adverse 
effect developed early after starting the drug were not included in the study.   
 
  
Electronic medical records from the RMRS were used to identify incident 
users. One year was selected as the period during which patients should not have 
received NSAID prescription (Figure 7). Information was collected on relevant 
confounders at baseline. Blood pressures were abstracted at baseline and post-
index. The end date of follow-up was defined as one year after the first prescription 
or 30 days after the last prescription that was dispensed, whichever was less. A 
thirty-day period was selected because most prescriptions last for one month.  
Patients with normal blood pressure may not present to the clinic during the 
first few months after their index date. And some patients may miss their 
appointments and not visit the clinic as frequently as scheduled. Considering this 
Time 
Incident user:       
               Subject A 
Prevalent user:       
                                    
                  Subject B 
             
 
                  Subject C 
      Index date             
(Time enrolled in study) 
 
 
 
 
First  
Rx 
End 
Point 
End 
Point 
Drug 
Stopped 
No use of index drug  
First  
Rx 
First  
Rx 
 53 
possibility, a one year follow-up was chosen to avoid bias from excluding some 
hypertensive patients.  
Figure 7. Different Scenarios for Patients’ Follow-up Periods  
 
Subject A: subjects with multiple prescriptions for more than one year are followed for only 
one year. Subject B: subjects with multiple prescriptions for less than one year are followed 
for 30 days after the last prescription. Subject C: subject with only one prescription is 
followed for only 30 days. Patients were followed to their first blood pressure measurement.     
Control Group  
Hypertensive patients who were prescribed acetaminophen formed the 
control group. NSAIDs and acetaminophen are both used for the pain associated 
with arthritis as well as other types of pain. Acetaminophen is usually prescribed as a 
first line therapy for patients with osteoarthritis (92). If the patient does not respond 
to acetaminophen, then the prescriber may switch to a NSAID. Thus, users of 
acetaminophen are similar to users of NSAIDs in most characteristics and 
comorbidities.  
1 year 1 year 
Time 
Subject   A 
Multiple Rx for 
MORE than 1 
year 
Subject   B 
Multiple Rx for 
LESS than 1 year 
Subject   C 
Only ONE Rx 
Index date 
(first NSAID or Acetaminophen prescription) 
No use of index drug 
No use of index drug 
No use of index drug 
 
 
End date 
Last refill End date 
End date 
30days 
30days 
Only 1 Rx 
 
Last refill 
 54 
The use of acetaminophen for the control group may be criticized, as some 
studies have shown an increase in blood pressure associated with the use of 
acetaminophen. In one short-term randomized crossover trial of 20 patients, the use 
of acetaminophen was associated with a 4 mmHg increase in systolic blood 
pressure (102). However, another randomized trial that included 45 patients found 
no blood pressure increase in the acetaminophen group (32).  
Two analyses of the Nurses’ Health Study, which included only women, found 
an increased risk of hypertension among users of acetaminophen (26, 27). Bias 
could have been introduced in these studies since self-report was used to ascertain 
hypertension diagnosis and acetaminophen use. In contrast, acetaminophen did not 
increase the risk of hypertension in the Physicians’ Health Study (28). Again, self-
report was used to ascertain exposure to acetaminophen and study outcome. The 
study outcome was self-reported blood pressure of 140/90 mmHg or higher, or the 
use of antihypertensive medication (28). Another recent analysis of the Physicians’ 
Health Study that included a larger number of subjects found a relative risk for 
incident hypertension of 1.34 associated with acetaminophen (95% confidence 
interval, 1.00 to 1.79) (103).  
It is unclear whether these conflicting results are because of gender 
differences or because of limitations in study design. In the above-mentioned 
studies, the investigators did not confirm the self-report of hypertension diagnosis. 
Since self-report was used to ascertain both exposure and outcome, 
misclassification bias is a major threat to these results. Also, these studies did not 
sufficiently control for all comorbidities. Furthermore, these studies noted diagnosis 
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of incident hypertension but did not measure blood pressure. It is important to 
mention that all these observational studies used similar design and populations. 
Thus, the evidence that acetaminophen is associated with blood pressure increase 
remains relatively weak.  
In the current study, patients who were prescribed acetaminophen had similar 
characteristics and comorbidities to NSAID users at baseline (Table 3). Propensity 
score methods were used to balance covariates between the compared groups. 
Acetaminophen is used mostly for pain, and pain is independently associated with 
stress, which could lead to hypertension (104). This confounding by indication was 
controlled for by using propensity score to balance the diagnosis of RA and OA 
between the compared groups. The index date for the control group was the date of 
the first acetaminophen prescription. To be included as a control, the patient should 
not have had a prescription for acetaminophen during the year before the index date 
and should meet the same inclusion criteria as for the NSAID group. The 
ascertainment of the baseline covariates and exposure to acetaminophen was 
applied in the same way as for users of NSAIDs.  
Sample Size 
A minimum sample size was calculated for each aim of the study. Based on 
the dependent variable, multiple linear or logistic regression models were used. For 
multiple linear regression models, the sample size was calculated using methods 
proposed by Cohen 1988 (105). To be conservative, alpha was adjusted for the 
number of hypotheses included in the study to be 0.05/10=0.005. A minimum sample 
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size of 138 was needed for multiple linear regression to achieve 80% power using 
alpha of 0.005 (number of predictors=33, effect size=0.35) (105).  For logistic 
regression, the minimum total sample size of 909 (total of both groups) was needed 
to detect an odds ratio of 2.3 (alpha 0.005, beta 0.80) (106). A sufficient number of 
patients were identified for each aim (Table 4).  
Dependent Variables 
Aim 1 and Aim 2: First systolic blood pressure measurement post-index 
The systolic blood pressure measurement was included in the model as a 
continuous variable. This continuous variable enabled this study to examine the 
magnitude of NSAIDs’ effect on blood pressure. The first measurement post-index 
was selected, as physicians may react to blood pressure increase by changing 
antihypertensive therapy. Systolic blood pressure was selected because it is 
associated more with morbidity and mortality than diastolic and should be targeted in 
the treatment of high blood pressure (19). After age 50, systolic blood pressure 
presents a more potent cardiovascular risk factor than diastolic. In addition, 
controlling isolated systolic blood pressure reduces total mortality, cardiovascular 
mortality, and stroke (19).  
According to JNC 7, systolic and diastolic are used to classify blood pressure 
into four categories, namely: normal, pre-hypertension, stage one hypertension, and 
stage two hypertension. To be considered normal, blood pressure must be lower 
than 120/80 mmHg. Pre-hypertension is defined as systolic blood pressure of 120-
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139 mmHg or diastolic blood pressure of 80-89 mmHg. Hypertension is considered 
stage one when systolic blood pressure increases to 140-159 mmHg or diastolic 
blood pressure to 90-99 mmHg, and stage two if systolic blood pressure is ≥160 
mmHg or diastolic blood pressure is ≥100 mmHg (19).  
Tierney et al. found in the same study population that one blood pressure 
reading has significant prognostic value (107). The study included 5,825 
hypertensive patients from RMRS who were followed for about 5 years. A 10 mmHg 
increase in systolic blood pressure from a single clinic visit was associated with a 
13% increased risk of renal insufficiency, a 9% increased risk of ischemic heart 
disease, and a 7% increased risk of stroke. The researchers concluded that, in 
hypertensive patients, a single blood pressure measurement has an important 
prognostic effect and physicians need to intervene to lower blood pressure based on 
a single measurement (107). Thus, the increase in one blood pressure value is 
clinically important, and using the first measurement is appropriate to study the 
association between NSAIDs and blood pressure. 
Aim 3:  Changes in antihypertensive therapy 
Blood pressure increase after starting NSAIDs could influence the physician’s 
decision to intensify antihypertensive therapy. Changes in antihypertensive therapy 
post-index were considered intensified when: (1) the dose of any one of the current 
antihypertensive medications was increased; or (2) the patient was started on a new 
antihypertensive medication from another class. A dummy variable was generated 
with “1” if antihypertensive therapy was intensified and “0” if not. 
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Independent Variables 
Based on previous literature, the models included certain covariates that 
could affect blood pressure or the use of NSAIDs including age, race, gender, and 
baseline systolic blood pressure. Baseline systolic blood pressure was defined as 
the last measurement before the index date. The models controlled for the diagnosis 
of certain diseases, the use of, and adherence to, antihypertensive medications, the 
use of medications that are known to be associated with blood pressure increase, 
time from baseline blood pressure measurement until the index date, and year of the 
index date. Table 5 lists the variables included in this study, their types, units, and 
definitions. For these categorical independent variables, a dummy variable was 
generated with “1” as yes and “0” as no.  
The diagnosis of the following conditions at baseline was included in the 
models: rheumatoid arthritis, osteoarthritis, coronary artery disease or myocardial 
infarction, stroke (cerebrovascular accident or transient ischemic attack), arrhythmia 
or ventricular arrhythmia, asthma or chronic obstructive pulmonary disease, renal 
insufficiency, cirrhosis with ascites, systemic lupus erythematosus, diabetes mellitus, 
and congestive heart failure. These comorbidities serve to differentiate sicker from 
healthier patients. For each comorbid condition, a dummy variable was generated 
that equaled “1” if the condition is present and “0” if not.  
The analysis controlled for the use of medications that are known to be 
associated with increase in blood pressure or incidence of hypertension. Based on 
previous literature, the use of venlafaxine, a high dose of oral glucocorticoids, and 
the use of oral contraceptives were included in the models (108-112). Oral 
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glucocorticoids that were identified in the database were prednisone, cortisone, and 
dexamethasone. A high dose was defined as 10 mg or higher for prednisonse, 50 
mg or higher for cortisone, and a dose of 1.5 mg or higher for dexamethasone.  
The patient’s age at the index date was included in the model as a continuous 
variable. For gender, a dummy variable was created that equaled “1” if female and 
“0” if male. For race, three dummy variables were created, African-American, 
Caucasian, and other. The Caucasian category was used as the reference group.  
Exposure to Index Drug 
Including exposure to the index drug (NSAID or acetaminophen) is important 
to adjust for the variation in the treatment intensity. For example, patients who are 
using NSAIDs only as needed might have a different blood pressure response from 
those who are taking NSAIDs daily. The database used does not include a variable 
to indicate whether the drug was prescribed to be taken as needed. Previous 
literature did not offer any method that could capture exposure in terms of regular 
versus as-needed use. Several options were considered to control for variations in 
exposure to the index drug, including medication gap between refills, medication 
possession ratio (MPR), and the number of refills per month. Gap between refills 
does not add any new information to address the as-needed issue beyond that 
provided by MPR, since it is the opposite of MPR adherence (113). Gap would be 
more relevant if withdrawal effect of medications were a concern.  
Therefore, MPR and the number of refills per month were used to control for 
variation in exposure to the index drug. The MPR is the refill adherence and was 
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calculated by dividing the sum of the days between the last refill and the next 
expected refill (i.e. days supply) by the number of days between the last refill and the 
next actual refill, then multiplying by 100 to obtain the percent MPR (Equation 1). For 
each patient, an average MPR was calculated for the index drug.   
( )1100
fill last until onprescripti first from days total
 obtainedsupply  days' the of sum
 (MPR) Ratio Possession Medication ×=
 
The MPR was included as a categorical variable because it had multi-modal 
distribution. Prior research did not use the MPR to ascertain exposure to NSAIDs or 
acetaminophen. In the current research, categories with perceived clinical 
meaningfulness were created for the MPR (<20%, 20% – 80%, >80%). The first 
category (<20%) will be more likely to include patients who are using the index drug 
minimally or as needed. The second category (20% – 80%) captures patients using 
the drug on a regular basis but who are likely to be non-adherent. The third category 
(>80%) includes adherent patients. A sensitivity analysis was conducted using ±10 
around the categories of MPR (10% or 30%, 70% or 90%). For patients prescribed 
the index drug only once, the MPR was calculated by assuming it lasted for 30 days, 
the mean quantity supplied duration.  
As a proxy for as-needed versus regular use, the number of refills per month 
was included in the model. Doing so assumes that the patient refills regularly and as 
such exposed to the drug on a continuous basis (regardless of whether it was 
prescribed for as-needed or regular use). The number of refills was calculated for 
each subject. The interval was then calculated by subtracting the index date from the 
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service date of the last prescription. If a patient had only one prescription, then the 
interval was calculated by subtracting the index date from the expected finish date. 
The refills per month were calculated by multiplying the number of refills by 30 and 
dividing it by the interval. Since refill per month is not normally distributed, a dummy 
variable was created that equaled “1” if the subject had one refill per month or more, 
and equaled “0” if the subject had less than one refill per month.  
In addition, two sensitivity analyses were conducted. In the first analysis, the 
model included the extent of exposure as the dose-MPR interaction. In the second, 
the analysis was restricted to only those patients who had a blood pressure 
measurement within 30 days of the index date.  
The Use of Antihypertensive Medications 
Baseline use of antihypertensive medications was included amongst the 
covariates in the models. Five groups of antihypertensive medications were formed: 
beta-adrenergic antagonists, CCBs, diuretics, ACE-I or angiotensin II receptor 
antagonists, and other antihypertensive medications. The frequency distribution of 
the baseline antihypertensive medications class is listed in Table 3. The regression 
model included all the dummy variables for the class of antihypertensive 
medications, and the reference group consisted of those hypertensive patients who 
were not prescribed any antihypertensive medication.  
The effect of NSAIDs on blood pressure was compared across 
antihypertensive medications using a sub-analysis for each antihypertensive class. A 
sub-analysis was used instead of interaction terms for several reasons. Compared to 
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experimental studies, the joint distribution of interacting terms in observational 
studies might not be optimal, resulting in an incorrect estimate of the effect (114). 
Another problem is that multi-collinearity created from using interaction terms inflates 
the variance of the estimate, resulting in wide variations in the estimate from sample 
to sample. Also, multicollinearity increases the magnitude of the parameter estimate, 
making it appear to have much stronger effects (114).  
Propensity score matching techniques were used to balance background 
characteristics between compared groups for each class of antihypertensive 
medications. Four classes of antihypertensive medications were examined: beta-
adrenergic antagonists, CCBs, diuretics, and ACE-I. Included patients had to be 
taking the antihypertensive medication at baseline, had no changes in therapy post-
index, and had a prescription during the assessment of systolic blood pressure. This 
was accomplished by requiring patients to have a prescription filled before or on the 
day of the systolic blood pressure measurement; and the end date for the same 
prescription had to be after the day of the measurement. For each antihypertensive 
class, a dummy variable was created that equaled “1” if the patient was prescribed a 
medication within the antihypertensive class and “0” if not. 
Adherence to Antihypertensive Medications 
Adherence to antihypertensive medications was included in the models as it 
directly affects blood pressure. Compared to variations in exposure to NSAIDs, 
patients prescribed antihypertensive medications are expected to use it regularly. 
Previous literature has suggested methods to assess adherence to medications 
 63 
used for chronic diseases that include use of medications refill, pill count, electronic 
monitoring, biomarkers, and asking the providers or the patients (113, 115). The 
database used in the current study, RMRS, includes the pharmacy prescription refill. 
Patients in this cohort receive their medications at subsidized costs. This makes the 
prescription database more complete and reflects the medications the patient is 
actually taking, including OTCs. Therefore, prescription refill adherence was used, 
by calculating MPR, to assess the level of adherence to antihypertensive 
medications. The use of MPR to assess medication adherence has been validated in 
several studies (113). MPR was calculated according to equation 1 above. 
Patients were considered adherent if they had an MPR of more than 80%. For 
each drug, an average MPR was calculated for a period of one year before the index 
date until the end date. Then the overall average adherence was calculated by 
dividing the sum of all the MPRs by the number of antihypertensive medications that 
the patient was taking (116).  
Year of Index Date 
This study includes patients who started using NSAIDs between 1993 and 
2006. During this period, information was evolving about the association between 
NSAIDs and blood pressure increase. Thus, the physician’s decision to prescribe 
NSAIDs for hypertensive patients could change depending on the year of the index 
date. In addition, recent clinical trials and guidelines are now recommending more 
aggressive treatment to control blood pressure. Therefore, the propensity for 
adjusting antihypertensive therapy may vary by date. To counteract the effect of 
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these factors on the results, the model included the year of index date. The year 
variable was divided into three categories: from 1993 through 1996, from 1997 
through 2002, and from 2003 onwards. The cut-off points of 1997 and 2003 were 
selected as JNC 6 was released in 1997 and JNC 7 was released in 2003. The 
release of an updated version of the JNC report may affect future prescribing 
practice as the goals of blood pressure control may intensify and recommendations 
for selection of antihypertensive medications may change. 
Time between Baseline Blood Pressure and the Index Date 
The time between baseline blood pressure measurement and the index date 
could vary between the patients included in the study. Many factors could have 
affected blood pressure in the interval before the patient commenced taking the 
index drug. Blood pressure could vary for those with a longer period between 
measurements and the index date; therefore, baseline measurement may not 
represent the current baseline accurately. Ideally, baseline blood pressure 
measurement should be closer to the index date and measured at the same time for 
all patients. Since patients have a clinic visit on the same day as they are prescribed 
the index drug, it is expected to find many patients with a baseline blood pressure 
measured at the index date. However, patients do not always pick up their 
prescription on the same day as they visit the clinic.  
To prevent bias introduced by variations in the time from baseline blood 
pressure measurement until the index date, a variable to indicate this time was 
included in the model. This variable was constructed by subtracting the date of the 
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last baseline systolic blood pressure measurement from the index date. Since time 
was not normally distributed, it was divided into three categories: less than or equal 
to 7 days, more than 7 days and equal to or less than 30 days, and more than 30 
days before the index date.  
Dose Analysis  
The last dose that the patient was stable on at baseline was selected. Since 
dose was not normally distributed, patients were stratified into low and high dose 
groups. Patients who were prescribed less than 75% of the maximum daily dose 
were included in the low dose category and those prescribed 75% or more were 
included in the high dose category. The maximum daily dose was obtained from the 
drug reference Facts and Comparisons (117). 
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Propensity Score Analysis 
Several studies indicate that comorbidities could influence the prescribing of 
selective COX-2 inhibitors compared to non-selective NSAIDs (94-97, 118). This 
emphasizes the importance of controlling for these factors in the analysis. In 
observational studies, different analytical techniques can be used to control for 
covariates when assessing treatment effects. The most commonly used are model-
based techniques. This approach of using modeling is limited, in that it runs 
statistical analysis and display results without warning when compared groups are 
not balanced on covariates. In contrast, the propensity score method warns the 
investigator of inadequate overlapping of covariates.  
The propensity score is mainly used to balance covariates between compared 
groups in observational studies. It is the estimated probability for each subject of 
being exposed to treatment A versus treatment B, based on the person’s covariates. 
It combines all confounding covariates into a single composite factor. For each 
comparison, a different propensity score needs to be estimated (44, 119, 120). 
Rosenbaum and Rubin introduced the propensity score as the conditional probability 
of the assignment to treatment given the subject’s covariates, assuming that Z is 
independent given x (121): 
( ) ( ) ( )21 xzprxe ==  
General steps to conduct the propensity score are suggested in the literature 
(Figure 8) (44). The first step is to estimate the propensity score for each patient 
based on the observed covariates. The most common method for propensity score 
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estimation is to conduct a logistic regression, where the treatment is the dependent 
variable regressed over other covariates. Then the logit is calculated from 
probabilities as in the equation (3).  
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Figure 8. General Steps to Conduct Propensity Score 
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Variables that predict exposure to treatment are included in the propensity 
score model. Excluding variables that predict outcome will increase variance and 
result in a less optimal propensity score model. (122) Therefore, in addition to 
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are related to the outcome of interest should be included when predicting the 
propensity score.  
After calculating the propensity score, the score can be used in three different 
ways to balance covariates among compared groups: (1) matching samples of 
exposed and control patients who have a similar propensity score; (2) stratifying 
patients based on their propensity score, usually in five balanced groups; (3) 
including the propensity score as a covariate in a multivariable model (i.e. regression 
adjustment) (119, 123, 124). Covariate adjustment is biased if the covariance 
matrices in the treated and control groups are unequal. Therefore, matching and 
stratification are considered superior to covariance adjustment (123). The current 
study used the propensity score matching method because matching is sometimes 
superior to sub-classification in providing more comparable groups.  
Matching can be applied using different methods including nearest neighbor 
and 1 to 2 matching, radius matching, kernel matching, and Mahalanobis metric 
matching. In the nearest neighbor method the treatment and control subjects are 
randomly ordered, then the first treatment is selected and matched with one (two for 
1 to 2 matching) control with the closest propensity score (Figures 9 and 10). This 
method could result in unbalanced matches if the caliper is not used (125).  
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Figure 9. Nearest Neighbor Matching Method (1 to 1) 
 
 
Figure 10. Nearest Neighbor Matching Method (1 to 2)  
 
In radius matching, each treated subject is matched only to a control whose 
propensity score falls in a predefined radius of the treated propensity score. This will 
result in more balanced groups since matching within this radius will occur with a 
similar control. However, it is difficult to decide which radius to use (125). 
Kernel matching involves assigning weight to control. This weight is inversely 
proportional to the distance between the propensity scores of treated and control 
subjects. Then, treated subjects are matched with a weighted average of all the 
controls. A lower distance between propensity scores means a higher weight and 
this results in a good match (125). 
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* Each treated subject is matched with one control subject with the same or closest propensity score.  
* Each treated subject is matched with two control subjects with the same or closest propensity score.  
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Matching using the Mahalanobis metric is another popular method which has 
been used before for bias reduction in observational studies (126). The Mahalanobis 
metric works by randomly ordering subjects and then calculating the distance 
between the first treated subject and all controls. The distance is defined as: 
( ) ( ) ( ) ( )4, 1 vuCvujid T −−= −  
Where u and v are the values for the matching variables for treated and 
control subject ( )ji, , and C is the sample covariance matrix of matching variables 
from the full set of control subjects (123). Each treatment subject will be matched to 
a control subject within a predetermined range of the treated subject’s estimated 
propensity score (125, 127).  
Lack of overlap in propensity score between treatment groups means that 
they are not comparable, and thus the use of propensity score matching may not be 
helpful (Figures 11 and 12). The use of a caliper with any of the above-mentioned 
methods can restrict the matching of treatment subjects to control subjects with a 
common support region. Caliper is a predefined range of the subject’s predicted 
propensity score. By using the caliper the matching of treated subjects can be 
restricted to controls with a common support region. After defining the caliper a 
random treated subject is matched with a control based on a propensity score within 
this caliper. When using a caliper, some subjects will be unmatched resulting in a 
smaller sample, but a between-group balance will be achieved. It is important to note 
that subject loss occurs when using a caliper when the treatment and control groups 
do not have a good overlap in covariates. Where overlap exists, comparisons are 
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valid. It was suggested to use one-fourth standard deviation of the estimated 
propensity score (128). After defining the caliper, one treated subject is randomly 
selected and matched with a control based on the propensity score within this 
caliper (125).  
Figure 11. Lack of Overlap in Propensity Scores between Treatment and Control  
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Figure 12. Overlap in Propensity Scores between Treatment and Control  
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All matching methods can be used with or without replacement. In matching 
without replacement, control subjects are dropped from consideration once they 
were matched to treated subjects. Thus, each control is used only once in the final 
dataset. When overlap between treated and control subjects does not exist, 
matching without replacement could lead to poor matches. To solve this, it was 
suggested that matching with replacement be used to improve the matching 
process. With replacement, a control subject could be matched to more than one 
treated subject (Figure 13). Allowing replacement increases the balance of 
covariates between the matches. However, replacement reduces the number of 
distinct control subjects included, thus increasing the variance of the estimator (129). 
In addition, replacement may not improve the balance of covariates between the 
treatment and control groups. 
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Figure 13. Nearest Neighbor Matching Method with Replacement 
 
In a recent sensitivity analysis, the Mahalanobis matching method yielded 
better results than all other matching methods (125). The matching methods 
compared included: nearest neighbor, 2 to 1 matching, Mahalanobis, Mahalanobis 
with caliper, radius matching, kernel matching, and stratification. The author used 
criteria from five tests to compare the balance of covariates between various 
methods of matching. First, two sample t-statistics tests were used to compare the 
variables’ means between the treatment and control groups (chi-square was used for 
categorical variables). Second, the mean difference was compared as a percentage 
of the average standard deviation. Third, the percentage reduction of bias in the 
means of variables was compared between various matching methods. Fourth, the 
Kalmogorov-Smirnov test was used to compare the density estimates of the 
explanatory variables between treated and control subjects. Fifth, the author 
compared the density estimates of the propensity scores between treated and 
control subjects (125). Mahalanobis with caliper was found to have the best 
matching on variables. The outcome was estimated by examining the difference in 
means between treated and control groups. Also, standard errors were decreased by 
threefold when a regression analysis was conducted after propensity score matching 
Matched pair 
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* In matching with replacement a control subject could be matched to more than one treated subject.  
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(125). Therefore, applying a regression analysis after propensity scores matching 
may improve the precision of the estimate.  
Mahalanobis metric matching without replacement method was used in the 
current study since it produces a better balance between the covariates in the 
treated and control groups (123, 125). This research included variables in the model 
based on a theoretical framework and knowledge of the disease and medications, 
before examining the balance between covariates.  
The choice of the statistical software affects the covariates balance and 
ultimately the study’s results. PSMATCH2 in STATA software for propensity score 
matching was not used because the Mahalanobis matching is conducted only with 
replacement. To match without replacement, all matching duplicates need to be 
deleted after matching; however, this is inappropriate as some treated subjects 
would be lost in this process. Therefore, this study used a macro code within SAS 
software to implement Mahalanobis matching without replacement from the 
beginning. Propensity scores were predicted using the PROC LOGISTIC procedure 
in SAS/STAT software. The logit was calculated and then the subjects were matched 
based on their propensity score using the Mahalanobis matching method without 
replacement. A caliper of one quarter of the standard deviation of the propensity 
score was used (± 0.25 * standard deviation).  
The next step after matching subjects is to assess the balance of covariates 
across the two groups. A chi-square test for categorical variables and Student’s t-test 
for continuous variables were used to assess the covariate balance. Another method 
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to assess balance is standardized difference. The standardized difference is the 
mean difference between the two groups as a percentage of the average standard 
deviation (123, 127) (Equation 5). 
Standardized difference = 
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The goal is to keep this difference as small as possible. Also, the percentage 
of bias reduction achieved by the estimated propensity score can be calculated 
using Equation 6. The percent bias reduction is the bias reduced for each variable 
by using the propensity scores method. It is calculated as the absolute value of the 
standardized difference in means for the matched divided by the absolute value of 
the standardized difference in means for the unmatched, which is then subtracted 
from one and multiplied by 100 to obtain the percentage of bias reduction.  
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In the current study, the balance of covariates between the groups was 
examined using the chi-square test for categorical variables and Student’s t-test for 
continuous variables. Also, the standardized difference and the percentage of bias 
reduction were calculated. After satisfied with covariate balance, a multiple linear 
regression model was used to study the effect of NSAIDs on systolic blood pressure 
and changes in antihypertensive therapy. The key independent variable was the use 
of NSAIDs. Covariates that were not balanced by propensity score matching were 
included in the regression model. Also, the model included the time from index date 
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until blood pressure measurement, since this time occurred after the index date it 
could not be included in the propensity score matching. Another advantage of using 
a regression model is that it reduces the standard error and, hence, improves the 
precision of the estimate (125).   
Adjustment for Multiple Comparisons 
The term ‘multiple comparisons’ refers to the comparison of the mean values 
when multiple treatments are involved (130), while ‘multiple testing’ refers to all tests 
and hypotheses included in a study. When a number of hypotheses are tested, the 
chance of making a Type I error increases. This would result in a false significant 
difference. For this reason, some researchers have recommended adjusting the p-
values for the number of hypotheses tested in a study (130, 131). In contrast, other 
researchers argue that this adjustment might lead to inaccurate decision and an 
increase in the likelihood of a Type II error (132, 133).  
Adjusting the p-value for multiple comparisons is undertaken because multiple 
testing increases the chance of finding statistically significant results. To prevent this 
from occurring a smaller p-value is used to ensure that the error for all tests remain 
at 0.05. One method to adjust for multiple comparisons is the Bonferrroni 
adjustment. However, compared to other methods this is considered by most 
researchers to be more conservative. Alternatively, other methods such as 
confidence intervals, Bernoulli, Hochberg, and Tukey are used to adjust for multiple 
comparisons (132, 134-136). The selection of adjustment method depends on the 
type of comparison. For example, Tukey can be used in a one-way unbalanced 
 77 
analysis of variance. However, when covariates are included in the general linear 
model, a simulation method is recommended, because other methods do not fully 
exploit the correlation structure (130, 131).    
Several reasons for not adjusting the p-value are discussed in the literature 
(132, 133). By reducing the chance of making a type I error, the chance of making a 
type II error of not finding a difference when there is one increases. As a result, 
important differences could be missed. In addition, adjusting the p-value increases 
the sample size needed in a given study. Also, current methods used for adjustment 
have limitations, and some may not adjust the p-value appropriately. Other ways to 
handle the multiple comparisons issue include the use of a composite endpoint to 
limit the number of tests and the selection of one primary endpoint and several 
secondary endpoints (132).  
In the current study, simulation was used to adjust for multiple comparisons; 
because in the general linear model other methods such as Tukey-Kramer do not 
fully exploit the correlation structure (130, 131). The simulation works by drawing a 
random sample from the standard normal distribution to compute the test statistics 
for all pairwise comparisons. This process is repeated multiple times to estimate the 
simulation-consistent estimate and calculate the adjusted confidence interval and P 
value (130). In this study, confidence intervals and P values were adjusted for 
multiple comparisons by simulation using the ADJUST=SIMULATE option in SAS 
GLM procedure. Multiple comparisons were adjusted for only when more than two 
treatment levels were compared in the same regression model. An alpha of 0.05 
was used in the analysis. When adjusting for multiple comparisons, the value of 
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alpha will be smaller, based on the adjustment. Since the number of hypotheses to 
be tested in this study is not large and the study is exploratory, no adjustment was 
made for multiple testing. 
Missing Data on Dose 
Missing data on dose was encountered in this database. Missing data on 
some variables is a common problem in observational studies and clinical trials. 
Several mechanisms explain the relationship between missing data and variables 
included in the study. A typical mechanism is “missing completely at random” 
(MCAR). MCAR means that missing data on a variable is unrelated to the value of 
any variables in the model, including its own true value (137, 138). This is the 
strongest assumption and it is not possible to see whether missing data are 
correlated with the value of the variable itself. “Missing at random” (MAR) is another 
mechanism in which missing values may depend on observed variables, but 
conditional on those values data are missing randomly. For example, data on Y are 
said to be MAR if these data are not related to the value of Y after controlling for 
other observed variables in the analysis. Thus, in MAR, missing values do not 
depend on the values of unobserved variables. The last mechanism is “not missing 
at random” (NMAR) in which missing values do depend on unobserved values (137, 
138). 
There are several approaches to handling missing data including the use of 
dummy variable adjustment, imputation by substituting the mean or conditional 
mean imputation, and complete case analysis. In the dummy variable adjustment 
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method, missing data are recoded to zero and a dummy variable is included to 
indicate which observations were missing. The major limitation of this method is that 
it can introduce bias (137).  
Imputation is another method to handle missing data and can be done by 
either substituting the mean or substituting the mean that was regressed on other 
covariates. When data are MCAR, imputation may not bias the results. It is a more 
efficient approach but the standard errors are incorrect (137).  
The complete case analysis method is the most commonly used and most 
statistical packages apply this automatically when a regression model is run. In this 
method, observations with missing values are dropped. One limitation of this method 
compared to other techniques is that the standard error is higher. However, this 
method is not biased with MCAR data and the standard errors and test statistics are 
correct. Also, this method is not biased if data are MAR and missing data depends 
only on independent variables (not dependent variable). Therefore, complete case 
analysis will not introduce bias in most situations, and thus is recommended over the 
other techniques discussed (137). In this study, complete case analysis was used for 
missing data on dose by dropping those particular observations.  
Over The Counter NSAIDs 
Some NSAIDs are available over the counter (OTC) in addition to by 
prescription and this database captures only the use of prescription NSAIDs. Bias 
could be introduced if patients were classified as non-users while they are using 
OTC NSAIDs. However, because patients included in this study were provided with 
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their medications through a prescription assistance program, it is less likely that they 
would have purchased OTC NSAIDs.  
Bias from not accounting for OTC NSAIDs is not likely to affect the results of 
the current study, as a recent sensitivity analysis was conducted that found that 
missing OTC drug exposure is not a significant source of bias even if the exposure is 
as high as 80% (139). This sensitivity analysis was conducted using published 
estimates of the association between NSAIDs and colorectal cancer. The 
investigators varied the overall prevalence of NSAID exposure (from 1% to 99%), 
the proportion of NSAIDs exposure due to OTC use alone, and the true risk ratio 
(0.25, 0.5, 0.75, and 0.9). They assumed that the proportion of NSAID exposure due 
to OTC use was the same between diseased and non-diseased individuals (non-
differential misclassification of exposure); and that the relative true risk used in the 
sensitivity analysis reflected the effect of NSAIDs on colorectal cancer. Also, they 
assumed that unexposed subjects were correctly classified as unexposed (139). 
The investigators concluded that, in many circumstances, prescription data 
may be sufficient for epidemiological research even though some of the drugs are 
available OTC (139). Even if 35% of the population uses NSAIDs and 80% of the 
NSAIDs used are OTC, the results will not be biased. As long as the proportion of 
exposure is similar between diseased and non-diseased people, misclassifying as 
unexposed will bias the effect estimate toward the null. In this study sample of 
subjects, it is less likely that OTC NSAIDs use would differ for the various groups 
under consideration. 
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Time to Blood Pressure Measurement 
The period of time from the index date until the measurement of blood 
pressure will vary between patients. Those who come to the clinic earlier could differ 
from other patients in certain respects, including the severity of diseases. To prevent 
bias caused by variations in time, patients could be stratified into several groups 
based on their time from the index date until the measurement of blood pressure, 
and several rounds of propensity score matching could then be conducted for each 
group. This option is appropriate if those patients who present earlier are strongly 
believed to have increased blood pressure. To explore whether patients with high 
blood pressure present to clinic earlier than those with normal blood pressure, the 
database was examined. No correlation was found between the time elapsing before 
blood pressure measurement and the value of systolic blood pressure (Figure 14).  
Another approach, to prevent bias caused by variations in time, is to include a 
covariate indicating the time from the index date until blood pressure measurement 
in the final model. Therefore, this study included the value for this time period as a 
covariate in the regression model after matching for propensity score.  
 
 
 
 
 
 
 
 
 
 
 82 
Figure 14. Systolic Blood Pressure by Time from Index Date until Blood Pressure 
Measurement 
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Average of Systolic Blood Pressure Measurements 
As discussed earlier, the use of a single blood pressure measurement is a 
reliable predictor of morbidity based on the work by Tierney et al. using the same 
database (107). To investigate this issue further, the results were compared when 
using an average of all blood pressure measurements to the results when using only 
a single measurement.  
Following the first prescription of NSAIDs, if the patient experienced an 
increase in blood pressure, detected at a clinic visit, physicians might increase the 
dose or start new antihypertensive medication. Thus, to prevent any potential effect 
of changing antihypertensive therapy on blood pressure, blood pressure 
measurements were included only until the date when the antihypertensive regimen 
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was changed. In the final regression model, the average systolic blood pressure was 
included as a dependent variable.  
Clinically Significant Increase in Systolic Blood Pressure  
Another analysis was conducted to investigate whether the increase in 
systolic blood pressure associated with NSAIDs is clinically important. Clinically 
important increase was defined as systolic blood pressure increase from baseline by 
at least 20 mmHg. The use of 20 mmHg was based on a previous study that 
investigated the effect of selective COX-2 inhibitors on blood pressure (71). A 
dummy variable was created that equaled “1” if systolic blood pressure increased by 
20 mmHg or more, and equaled “0” if not.  
 
 
 
IV. RESULTS 
 
 
Baseline Characteristics 
A total of 3,928 patients were prescribed NSAIDs (n=2,181) or acetaminophen 
(n=1,747) and met the inclusion criteria (Figure 15). As shown in Figure 16, baseline 
blood pressure measurements were within 30 days before the index date for most 
patients. Fifty percent (n=1,961) of patients included in the study had their baseline 
systolic blood pressure measurement on the index date (and more than 70% 
(n=2,788) within 30 days before the index date). Blood pressure measurements near 
the index date reflect the baseline in the ideal situation. However, more patients in 
the acetaminophen group had baseline blood pressure measurements closer to the 
index date compared to the NSAID group (P<0.001) (Figure 16).  
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Figure 15. Derivation of Cohort Size 
 
Figure 16. Percentage of Subjects in each Category of Time from Baseline Systolic Blood 
Pressure Measurement to Index Date by Index Drug 
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Time to blood pressure measurements was similar between NSAIDs and 
acetaminophen groups (P = 0.0773) (Figure 17). Forty two percent (n=1,650) of all 
subjects included in the study had their first systolic blood pressure measurement 
within 30 days after the index date. Changes in systolic blood pressure over time 
were similar between groups (Figure 18). The spikes in blood pressure at the end of 
the figure are due to the smaller sample sizes at later time points, which created 
greater fluctuation in the mean systolic blood pressure.  
Figure 17. Percentage of Subjects in each Category of Time from Index Date to First Systolic 
Blood Pressure Measurement by Index Drug  
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* P-value= 0.0773 for comparison of frequency between NSAIDs and Control (N=3,928).   
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Figure 18. Mean Change in Systolic Blood Pressure by Time to First Blood Pressure 
Measurement  
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* Change in systolic blood pressure = systolic blood pressure after index date – systolic blood 
pressure before index date (N=3,928).   
** Each line connects between means of change in systolic blood pressure for each treatment 
group (error bar: ± standard error). P-value was ≥ 0.1 for comparison between NSAIDs and 
acetaminophen at each time point. 
 
Most baseline characteristics differed between the NSAIDs and 
acetaminophen groups (Table 6). Patients in the acetaminophen group were older 
and had higher baseline systolic blood pressure. Also, more patients in the 
acetaminophen group had renal insufficiency, congestive heart failure, and other 
comorbidities. It is therefore important to balance these covariates between the two 
groups before estimating the changes in blood pressure. In the first aim of this 
dissertation the association between NSAIDs and systolic blood pressure was 
compared to those who were prescribed acetaminophen.  
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Results for Aim 1 
The association between NSAIDs and Blood Pressure Compared to 
Acetaminophen in Patients with Hypertension 
A total of 2,680 patients using NSAIDs or acetaminophen were matched 
(1,340 patients from each group). Matching on propensity scores resulted in 
balanced covariates between the two groups (Table 7). The standardized difference 
and bias were reduced in 33 of the 37 variables. Although four variables had an 
increase in bias after matching, none of the variables were statistically different 
between the two groups.  
Systolic blood pressure rose by 2 mmHg in patients who were prescribed 
NSAIDs compared to acetaminophen (95% confidence interval, 0.7 to 3.3; P = 
0.004; N=2,680) (Table 8). The results were similar when using the first or the 
average systolic blood pressure as the dependent variable. Since several blood 
pressure measurements were used to calculate the average blood pressure, the 
standard error was smaller and as such, the estimate was more accurate. Compared 
to acetaminophen, a prescription for NSAID was not associated with clinically 
important increase in systolic blood pressure (defined as increase by at least 20 
mmHg) (odds ratio, 1.17; 95% confidence interval, 0.96 to 1.43; P = 0.127). Patients 
who were prescribed an ACE-I, beta-adrenergic blocker, or a CCB had an increase 
in blood pressure associated with NSAID prescription. Compared to acetaminophen, 
a prescription for NSAID was associated with a 2.8 mmHg increase in average 
systolic blood pressure in patients who were prescribed an ACE-I (95% confidence 
interval, 0.2 to 5.4; P = 0.035; N=768), and a 5.5 mmHg increase in those prescribed 
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a beta-adrenergic blocker (95% confidence interval, 1.4 to 9.6; P = 0.008; N=340), 
and a 3.2 mmHg increase in those prescribed a CCB (95% confidence interval, 0.6 
to 5.7; P = 0.014; N=804). However, the increase in systolic blood pressure 
associated with NSAIDs in patients prescribed ACE-I or CCB was observed only in 
the average but not in the first systolic blood pressure analysis (Table 8). There were 
no statistically significant changes in systolic blood pressure associated with a 
prescription for NSAIDs in those prescribed a diuretic.  
A prescription for NSAIDs in patients who were prescribed combinations of 
antihypertensive medications was not associated with statistically significant 
changes in systolic blood pressure (Table 9). However, there was an increase in 
systolic blood pressure at alpha less than 0.1 in the combination of BB and ACE-I. 
Compared to acetaminophen, a prescription for NSAID was associated with a 7.5 
mmHg increase in systolic blood pressure in patients who were prescribed both BB 
and ACE-I (95% confidence interval, – 1.0 to 16.0; P = 0.084; N=108).  
Sensitivity Analysis of Exposure to the Index Drug 
Patients prescribed acetaminophen were more likely to have less than one 
refill per month compared to the NSAIDs group (P <0.001) and they were also more 
likely to have a MPR less than 20% (P <0.001) (Figures 19 and 20). Table 10 shows 
the result of the sensitivity analysis for the MPR and refills per month. The estimate 
of change in systolic blood pressure was not altered appreciably by changing the 
definitions of the MPR categories or refills per month. Therefore, the MPR was 
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included in the same three categories (<20%, 20% – 80%, >80%) and the refills per 
month in one category of one or more refills per month. 
Figure 19. Percentage of Subjects in each Refill per Month Category by Index Drug  
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* P-value <0.001 for comparison of frequency between NSAIDs and Control. N=3,928.   
 
Figure 20. Percentage of Subjects in each Medication Possession Ratio (MPR) Category by 
Index Drug  
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* P-value <0.001 for comparison of frequency between NSAIDs and Control. N=3,928.   
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In addition to the above two variables included to control for drug exposure, 
another sensitivity analysis was conducted that included only those patients who had 
a blood pressure measurement within 30 days after the index date. Forty two 
percent of patients had blood pressure measurements within 30 days after the index 
date. After propensity score matching, the result remained significant (systolic blood 
pressure estimate, 2.7 mmHg; 95% confidence interval, 0.55 to 4.89; P = 0.01).   
Summary 
Compared to acetaminophen, NSAID prescription was associated with a 
moderate increase in systolic blood pressure of 2 mmHg in patients with 
hypertension. Also, a prescription for NSAID was associated with a 3 mmHg 
increase in systolic blood pressure in patients who were prescribed ACE-I or CCB, 
and a 6 mmHg increase in those prescribed beta-adrenergic blockers. However, no 
statistically significant change in blood pressure was associated with NSAIDs in 
patients prescribed various combinations of two or more antihypertensive 
medications. In conclusion, prescribing NSAIDs was associated with a small 
increase in blood pressure in hypertensive patients compared to acetaminophen.  
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Results for Aim 2 
Effects of Specific NSAIDs on Blood Pressure  
A. Ibuprofen compared to naproxen: 
A total of 1,808 patients prescribed ibuprofen (n=1,313) or naproxen (n=495) 
met the inclusion criteria and had at least one blood pressure measurement before 
and after the index date. Most baseline characteristics were similar between patients 
in the ibuprofen and naproxen groups (Table 11).  However, some baseline variables 
were imbalanced, including race, baseline blood pressure, time from baseline blood 
pressure to the index date, year of the index date, diagnosis of renal insufficiency, 
adherence to antihypertensive medications, and exposure to the index drug. More 
than 95% (n=472) of patients prescribed naproxen were matched to patients 
prescribed ibuprofen. Matching on propensity scores resulted in balanced covariates 
between the two treatment groups (Table 11).   
Compared to naproxen, a prescription for ibuprofen was associated with a 2.5 
mmHg increase in average systolic blood pressure (95% confidence interval, 0.5 to 
4.6; P = 0.015). Compared to naproxen, ibuprofen was associated with clinically 
important increase in systolic blood pressure (defined as increase by at least 20 
mmHg) (odds ratio, 1.57; 95% confidence interval, 1.10 to 2.25; P = 0.014). The 
absolute risk in the ibuprofen group was 20.6% and in the naproxen was 14.6% and 
the calculated number needed to harm was twelve patients. Compared to naproxen, 
a prescription for ibuprofen was associated with a 5.9 mmHg increase in average 
systolic blood pressure in patients who were prescribed a beta-adrenergic blocker 
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(95% confidence interval, 0.0 to 11.7; P = 0.049; N=130) (Table 12). A prescription 
for ibuprofen in patients who were prescribed various combinations of two or more 
antihypertensive medications was not associated with significant changes in systolic 
blood pressure (Table 13).  
B. Ibuprofen compared to celecoxib: 
A total of 1,456 patients were using celecoxib (n=143) or ibuprofen (n=1,313) 
and were included to compare changes in blood pressure between the two treatment 
groups. Twenty-four covariates at baseline were imbalanced between the celecoxib 
and ibuprofen groups (Table 14). Based on their propensity scores, 113 patients 
from the celecoxib group were matched to the same number of patients from the 
ibuprofen group. Table 14 shows that propensity score matching resulted in similar 
covariate distributions between the two treatment groups. A prescription for 
ibuprofen was associated with a 5.2 mmHg increase in average systolic blood 
pressure compared to celecoxib (95% confidence interval, 0.4 to 10.0; P = 0.035) 
(Table 15). Compared to celecoxib, ibuprofen was associated with a clinically 
important increase in systolic blood pressure (defined as increase by at least 20 
mmHg) (odds ratio, 1.92; 95% confidence interval, 1.00 to 3.71; P = 0.050). The 
absolute risk in the ibuprofen group was 26.5% and in the celecoxib was 15.9% and 
the calculated number needed to harm was seven patients. 
C. Celecoxib compared to naproxen: 
Six hundred and thirty eight patients who were using celecoxib (n=143) or 
naproxen (n=495) were included in this analysis. One hundred and two patients from 
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the celecoxib group were matched to the same number of patients in the naproxen 
group. Matching on propensity scores resulted in balanced covariates between the 
two treatment groups (Table 16). A prescription for celecoxib was not associated with 
changes in systolic blood pressure compared to naproxen (change in systolic blood 
pressure, – 0.3; 95% confidence interval, – 5.1 to 4.5; P = 0.897) (Table 15). 
Compared to naproxen, celecoxib was not associated with a clinically important 
increase in systolic blood pressure (defined as increase by at least 20 mmHg) (odds 
ratio, 1.07; 95% confidence interval, 0.52 to 2.18; P = 0.855).  
D. Dose of NSAID: 
After propensity score matching, dose data were available for 54% (n=709) of 
patients who were prescribed ibuprofen and for 52% (n=258) of patients who were 
prescribed naproxen. The mean dose for ibuprofen was 2,053 mg (median was 2400 
mg) and the mean dose for naproxen was 908 mg (median was 1000 mg). Since 
dose was not normally distributed, patients were stratified in low and high dose 
groups. Patients who were prescribed less than 75% of the maximum daily dose 
were included in the low dose category and those prescribed 75% or more were 
included in the high dose category. Prescription of a high dose of ibuprofen was not 
associated with significant changes in systolic blood pressure compared to a low 
dose (change in average systolic blood pressure, 2.3; 95% confidence interval, – 1.3 
to 5.1; P = 0.3). Also, no significant change in blood pressure was associated with 
the prescription of naproxen in a high dose compared to a low dose (change in 
average systolic blood pressure, – 3.3; 95% confidence interval, – 9.6 to 3.1; P = 
0.4).  
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E. Dose and adherence of NSAIDs: 
The results did not change when a sensitivity analysis was conducted when 
the dose interaction with the MPR adherence was included in the model as a 
covariate. Similar to section “D” above, prescription of a high dose of ibuprofen was 
not associated with significant changes in systolic blood pressure compared to a low 
dose (change in average systolic blood pressure, 1.1; 95% confidence interval, – 2.1 
to 4.4; P = 0.7). Also, prescribing a high dose of naproxen was not associated with 
significant changes in systolic blood pressure compared to a low dose (change in 
average systolic blood pressure, – 2.4; 95% confidence interval, – 9.0 to 4.2; P = 
0.7).  
Summary 
Compared to naproxen, ibuprofen was associated with an increase in systolic 
blood pressure by approximately 3 mmHg. Also, a prescription for ibuprofen was 
associated with a 6 mmHg increase in systolic blood pressure in patients who were 
prescribed beta-adrenergic blockers. In addition, ibuprofen was associated with 
clinically important increase in systolic blood pressure compared to naproxen. The 
use of combinations of two or more antihypertensive medications was not 
associated with significant changes in blood pressure between naproxen and 
ibuprofen. Compared to celecoxib, ibuprofen was associated with a systolic blood 
pressure increase of 5 mmHg. No significant changes in blood pressure were found 
when comparing patients prescribed celecoxib to those prescribed naproxen. Neither 
ibuprofen nor naproxen demonstrated a dose effect. In conclusion, naproxen and 
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celecoxib were associated with a lower blood pressure increase compared to 
ibuprofen.  
Results for Aim 3 
The association between NSAIDs and Changes in Antihypertensive 
Therapy 
More patients were eligible for this aim since they were not required to have 
had a blood pressure measurement after the index date. A total of 6,849 patients 
prescribed NSAIDs (n=3,740) or acetaminophen (n=3,109) were eligible for inclusion 
in the analysis. Propensity scores were computed and 2,494 patients in the NSAID 
group were matched to the same number of patients in the acetaminophen group. 
Twenty nine of the 37 variables were imbalanced between the two groups before 
matching. After matching on propensity score, all variables were similar between the 
two groups except age (P = 0.008) and the diagnosis of coronary artery disease or 
history of myocardial infarction (P = 0.025) (Table 17). Therefore, these two 
imbalanced variables were included in the logistic regression model after propensity 
score matching. 
Change in antihypertensive therapy was defined as adding new 
antihypertensive medication from another class or increasing the dose of a current 
antihypertensive medication. Compared to acetaminophen, the prescribing of 
NSAIDs was not associated with a change in antihypertensive therapy (odds ratio, 
0.95; 95% confidence interval, 0.84 to 1.08; P = 0.4).  
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The association with change in antihypertensive therapy was compared 
between ibuprofen and naproxen. Eight hundred and seventy seven patients were 
prescribed naproxen and 2,227 were prescribed ibuprofen. More than 92% (n=805) 
of those in the naproxen group were matched based on their propensity scores to 
the same number of patients in the ibuprofen group. All covariates were balanced 
after matching (Table 18). A prescription for naproxen was not associated with 
statistically significant changes in antihypertensive therapy compared to ibuprofen 
(odds ratio, 1.06; 95% confidence interval, 0.84 to 1.33; P = 0.7).  
The effect of celecoxib on change in antihypertensive therapy was compared 
to ibuprofen and naproxen. One hundred sixty eight patients in celecoxib group were 
matched based on their propensity scores to the same number of patients in the 
ibuprofen group. A prescription for ibuprofen was not associated with statistically 
significant changes in antihypertensive therapy compared to celecoxib (odds ratio, 
1.44; 95% confidence interval, 0.74 to 2.82; P = 0.3). One hundred sixty seven 
patients in celecoxib group were matched based on their propensity scores to the 
same number of patients in the naproxen group. A prescription for naproxen was not 
associated with statistically significant changes in antihypertensive therapy 
compared to celecoxib (odds ratio, 1.56; 95% confidence interval, 0.79 to 3.11; P = 
0.2). Thus, prescription for NSAID was not associated with changes in 
antihypertensive therapy.  
V. DISCUSSION 
 
Summary of the Results 
This research examined changes in blood pressure after starting NSAIDs in 
patients with hypertension. Compared to acetaminophen, a prescription for an 
NSAID was associated with a small increase (2 mmHg) in systolic blood pressure in 
patients with hypertension. However, a prescription for an NSAID was not associated 
with clinically important increase in systolic blood pressure compared to 
acetaminophen (odds ratio, 1.17; 95% confidence interval, 0.96 to 1.43; P = 0.127). 
A prescription for NSAID was associated with a 3 mmHg increase in average systolic 
blood pressure in patients who were also prescribed ACE-I or CCB, and a 6 mmHg 
increase in those prescribed a beta-adrenergic blocker. The change in blood 
pressure was not statistically significant in patients prescribed diuretics or most 
combinations of multiple antihypertensive medications. A large increase in systolic 
blood pressure (7 mmHg) was observed in the combinations of beta-adrenergic 
blockers with other antihypertensive medications; however this increase was not 
statistically significant.      
For the second aim, ibuprofen was found to be associated with a 3 mmHg 
increase in systolic blood pressure compared to naproxen. Also, ibuprofen was 
associated with a 6 mmHg increase in systolic blood pressure in patients who were 
prescribed beta-adrenergic blockers. The use of various combinations of two or 
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more antihypertensive medications was not associated with significant changes in 
blood pressure between naproxen and ibuprofen. Compared to celecoxib, 
prescription for ibuprofen was associated with a 5 mmHg increase in systolic blood 
pressure (P = 0.035). A prescription for ibuprofen was associated with a clinically 
important increase in systolic blood pressure compared to naproxen or celecoxib 
(odds ratio, 1.57, P = 0.014; and odds ratio, 1.92, P = 0.050, respectively). The 
difference in blood pressure for patients prescribed celecoxib was not significantly 
different from those prescribed naproxen. There was no evidence of a dose-
response effect with ibuprofen or naproxen.  
For the third aim, prescription of NSAIDs was not associated with changes in 
antihypertensive therapy compared to acetaminophen. Patients prescribed 
ibuprofen, naproxen, and celecoxib had a similar probability of change in 
antihypertensive treatment. 
Interpretation of the Results 
Studies of medication safety often seek causal relationships between a drug 
and an adverse effect. Observational studies designed to investigate adverse drug 
effects demonstrate association, not causation. Several covariates other than 
prescription of the medication could explain a particular adverse effect. Investigators 
attempt to control for these covariates in the design and analysis stages; however, 
some important covariates are unknown or data are unavailable.  
Bradford Hill’s criteria remain among the best general guidelines for causal 
inference (140). When interpreting the results of this study the causality criteria need 
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to be considered. The cohort design of this study satisfies temporal relationship 
criterion, as blood pressure was measured after patients were started on NSAIDs. In 
contrast, some previous studies investigating the association between NSAIDs and 
the incidence of hypertension were conducted using a cross-sectional design. A 
problem with that design is that it might not satisfy the temporal criterion because a 
patient might have started the medication after the outcome had already occurred. It 
is more convincing that the association is causal when a biological mechanism 
exists for the adverse effect. Biological mechanisms explain most of the adverse 
effects observed in this study. For example, NSAIDs’ inhibition of PGs can explain 
some of their effects on blood pressure in patients prescribed a beta-adrenergic 
antagonist.  
This current research shows that NSAIDs are associated with increased 
blood pressure compared to acetaminophen in patients with hypertension. Although 
results were conflicting, previous studies suggested that acetaminophen was 
associated with blood pressure increase (26, 27, 102, 103). If blood pressure truly 
increases with acetaminophen, then the blood pressure increases observed in this 
research with NSAIDs is underestimated.  
The blood pressure increase associated with NSAIDs was greater in patients 
prescribed a beta-adrenergic antagonist than other antihypertensive medications. 
The reason for this variation in blood pressure among antihypertensives could be 
related to the degree of PGs inhibition and the differences among these medications 
in the antihypertensive mechanism. The blood pressure increase in patients taking 
NSAIDs and beta-adrenergic antagonists is consistent with the findings of two other 
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studies (10, 11). Similar to the current results, one meta-analysis reported a 6 mmHg 
increase in blood pressure in patients who were stable on beta-adrenergic 
antagonists and started NSAIDs (10). Another short-term clinical trial included 
patients who were taking propranolol and found that NSAIDs were associated with a 
7 mmHg increase in diastolic blood pressure (11). A proposed mechanism to explain 
this effect with beta-adrenergic antagonists is that inhibition of PGs by NSAIDs could 
increase sensitivity to the vasoconstrictor effects of sympathetic nervous system 
stimulation. Blocking beta receptors increases this sensitivity to the sympathetic 
nervous system, resulting in abolishment of the blood pressure lowering effect of 
beta-adrenergic antagonists (68). In addition, some beta- adrenergic antagonists 
reduce GFR and thus renal function (141). In the long-term, this could increase the 
sensitivity to blood pressure increase by NSAIDs.     
The blood pressure increase with NSAIDs in ACE-I users agrees with 
previous studies that reported a 5 to 10 mmHg increase in systolic blood pressure 
(13, 14, 16, 39). NSAIDs’ inhibition of PGs is the mechanism proposed explaining 
the loss of blood pressure lowering effect of ACE-I. Because PGs may mediate a 
component of the antihypertensive effect for ACE-I, NSAIDs’ inhibition of PGs could 
disrupt the blood pressure control achieved by ACE-I (14, 42, 65). Patients with 
diabetes mellitus who are diagnosed with hypertension are more likely to use ACE-I 
than other antihypertensive medications to preserve their kidneys and prevent 
nephropathy. Treatment of hypertension should intensify if a patient has diabetes 
mellitus (93); therefore, it is important to monitor blood pressure closely in diabetic 
patients who are prescribed NSAIDs to ensure adequate blood pressure control.  
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This study found an increase in blood pressure with NSAIDs in patients who 
were taking CCBs. In previous studies, blood pressure did not increase with NSAIDs 
in those who were stable on CCBs (13, 35, 36, 39). One explanation for this 
contradicting result is that previous studies did not detect this effect because of small 
study sample size. Another explanation is variability in the estimated true difference 
as this increase was observed only with the average but not first systolic blood 
pressure.  
The current study found no significant changes in blood pressure in those 
patients who were stable on diuretics. In two randomized clinical trials, the addition 
of ibuprofen did not affect blood pressure control with thiazides (33, 34). Current 
hypertension guidelines recommend starting patients on thiazide diuretics because 
they are associated with better clinical outcomes and fewer mortalities than other 
antihypertensive medications (19). In addition, diuretics are less expensive than 
other antihypertensive medications. Thus, diuretics are recommended to control 
blood pressure in hypertensive patients who need to be started on NSAIDs.  
No statistically significant changes in systolic blood pressure were associated 
with a prescription for NSAID in patients who were prescribed multiple 
antihypertensive medications. However, insignificant increases were found with 
combinations with beta blockers and ACE-I. Previous studies did not examine the 
combination of antihypertensive medications. In the current study, a minimum 
sample size of 138 was needed to detect large effect size difference (105). Because 
some of the combinations with beta-adrenergic blockers involved only small number 
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of patients, it is possible that this study was not statistically powered to detect small 
effects. 
The results of this study show that ibuprofen was associated with blood 
pressure increase compared to naproxen and celecoxib. A clinical trial that included 
97 hypertensive patients who were taking hydrochlorothiazide observed a smaller 
increase in diastolic blood pressure in naproxen users (1.8 mmHg) compared to 
ibuprofen users (2.6 mmHg) (12). Previous studies have shown that celecoxib was 
not associated with an increased risk of hypertension (29, 70, 71, 79) or increased 
blood pressure (3, 40-43, 75, 76).  
The difference between ibuprofen and naproxen could be due to the fact that 
a lower concentration of ibuprofen than naproxen is needed to inhibit COX-1 and 
COX-2 (142). Thus, doses are not likely comparable between naproxen and 
ibuprofen relative to COX enzyme inhibition. An explanation for the blood pressure 
increase with ibuprofen compared to naproxen or celecoxib is related to the 
frequency of dosing. Naproxen and celecoxib is often taken only twice daily while 
ibuprofen is taken four times daily; assuming that patients take their NSAIDs during 
the day (e.g. from 6 am to 9 pm) this may lead to greater spikes in blood pressure 
during the day with ibuprofen (Figure 21). These spikes in blood pressure would 
more likely be captured with clinic measurement of blood pressures such as those 
used in this study. Thus, blood pressure will be higher if it is measured at times 
during the day when the concentration of ibuprofen is high. A study reported that 
ibuprofen (short-acting NSAID) was associated with systolic and diastolic blood 
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pressure increase while piroxicam (long-acting NSAID) was not associated with 
changes in blood pressure (72).  
Figure 21. Blood Pressure Fluctuation Over 24 Hours Based on Dosing Frequency of NSAIDs 
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* Peaks are more likely with four times daily dosing of naproxen and celecoxib (at 6 am, 11 am, 
4 pm, and 9 pm) compared to twice daily dosing of ibuprofen (at 6 am and 6 pm).  
 
No dose effects were found for ibuprofen or naproxen. This may be explained 
by a lack of NSAID dose effect on blood pressure, the prescribed dose differed from 
the dose patients actually took, or patients prescribed a high dose experienced 
adverse effects, and could have stopped taking the drug temporarily or permanently. 
This study shows that the prescription of NSAIDs was not associated with an 
increased risk of changes in antihypertensive therapy. One explanation is that it may 
take a long time for these small effects to be clinically significant before physicians 
adjust the antihypertensive therapy.  
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Clinical Significance and Implications 
Hypertension is a prevalent cardiovascular disease. In the United States 
about 73 million people, or one in three, have high blood pressure (21). Blood 
pressure is only controlled in 35% of hypertensive patients (21). Poor blood pressure 
control increases morbidity and mortality, utilization of healthcare resources, and, 
ultimately, health care costs. In addition to other factors, the use of medications such 
as NSAIDs increases the risk of uncontrolled blood pressure.  
This research examined changes in blood pressure after starting an NSAID in 
patients with hypertension. The blood pressure increase associated with NSAIDs 
found in this study was small. In the long-term, small changes in blood pressure 
have important clinical and public health impacts. For example, decreasing systolic 
blood pressure by just 2 mmHg reduces stroke mortality by 10% and ischemic heart 
disease mortality by 7% (24). It stands to reason that a similar increment in blood 
pressure could result in the same percentage increase in adverse events. However, 
in the short-term this research found that a prescription for an NSAID was not 
associated with clinically important systolic blood pressure increase (defined as 
increase by at least 20 mmHg) or changes in antihypertensive therapy compared to 
acetaminophen. This should be interpreted in the light of possible increase in blood 
pressure with acetaminophen. Although results were conflicting, previous studies 
suggested that acetaminophen was associated with blood pressure increase (26, 27, 
102, 103). If blood pressure truly increases with acetaminophen, then blood 
pressure increase observed in this research with NSAIDs would be underestimated.  
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In the current research, ibuprofen was associated with an increase in blood 
pressure, but naproxen and celecoxib were not. This increase with ibuprofen was 
clinically important (systolic blood pressure increase by at least 20 mmHg). Patients 
prescribed ibuprofen, naproxen, and celecoxib had similar probability of change in 
antihypertensive treatment. Therefore, naproxen is a good option for patients who 
need NSAIDs and celecoxib for those at higher risk for adverse gastrointestinal 
effects. Before prescribing any new medication, it is important to consider both the 
benefits and adverse effects. Risks associated with NSAIDs need to be considered, 
including blood pressure increase, adverse cardiovascular effects, and 
gastrointestinal effects. For each patient, these adverse effects need to be balanced 
against the benefits of using these medications. To reduce adverse events, patient 
may participate in the decision to initiate treatment with NSAIDs so that they 
understand their risks. Patients should not take over the counter NSAIDs without 
consulting a health care provider. In addition, patients started on NSAIDs may need 
to self-monitor their blood pressure. 
Limitations 
This study has limitations that should be considered when interpreting the 
results. Patients included in this study came from a single health system and may 
not represent other practices. Hence, this study should be replicated in other 
settings and with different patients. Since this study used propensity score matching, 
risk factors for the increased blood pressure associated with NSAIDs were controlled 
and, as such, not investigated.  
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This research did not control for factors such as dietary sodium intake, 
physical activity, or alcohol consumption. These factors could affect blood pressure 
by 2 to 9 mmHg (19). This research captured adherence to medications by using 
refill adherence. Although the use of MPR refill adherence was validated in previous 
studies, it measures possession of medications by the patient and may not reflect 
what the patient is actually taking.  
In this study, controlling for as-needed versus regular use of medications was 
challenging. Patients may use NSAIDs regularly or as needed, depending on the 
severity of their symptoms. Thus, it was difficult to know how the patients were 
actually taking their medications, even if physicians’ instructions were collected. 
Nonetheless, the goal of this study was to determine whether blood pressure 
increase is associated with NSAIDs in patients from a general practice, who might 
use these medications as needed, regularly, or both. However, variation in drug 
exposure was controlled by including in the model both the MPR and the number of 
refills per month. In addition, the results did not change when sensitivity analysis 
was conducted that included only patients whose blood pressure was measured 
within 30 days after the index date.  
Clustering of physicians was not considered in this study. Clustering occurs 
when the intervention is delivered similarly to subjects who are treated by the same 
health care professional (143). Not adjusting for clustering inflates the standard 
error, thus reducing the power of the study. Cluster adjustment is only needed when 
the intervention depends on the skills of the health care professional and the time 
spent in patient education, which could vary from one provider to another. When the 
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intervention involves the use of medications, the outcome of the study depends 
mainly on the medication used and patient factors (143). Hence, clustering is 
unlikely to have affected the results of this study as patients from similar general 
internal medicine clinics were included. Also, no specialty clinics such as 
hypertension or pain clinics were used. This ensured that patients received similar 
follow-up and blood pressure monitoring. In addition, blood pressure measurements 
were those performed at scheduled clinic visits as opposed to walk-in or urgent visits 
wherein other factors such as stress could affect blood pressure.  
Propensity score matching was used to balance covariates at baseline. 
However, propensity score only balances the observed variables. Hence, the benefit 
gained from using the propensity score is dependent upon how well the relevant 
covariates were identified. In randomized studies, both observed and unobserved 
covariates have a greater likelihood of balance. The current research controlled for 
known covariates that affect the use of NSAIDs or blood pressure.  
Suggestions for Future Research 
Further studies are needed to confirm the results of this study and to answer 
questions related to the association between NSAIDs and blood pressure. Larger 
studies are needed to confirm the results of NSAIDs’ effect on blood pressure in 
patients using combinations of antihypertensive medications. Future studies may 
compare the effects of NSAIDs to both a control group of non-users and 
acetaminophen group. Mechanisms explaining variations in the loss of the blood 
pressure lowering effect among antihypertensive medications need to be explored. 
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The effect of NSAIDs on blood pressure depends on the individual NSAIDs used. 
The mechanisms for these differences among NSAIDs are not clear.  
It is unknown if the doses of antihypertensive medications affect the 
association between NSAIDs and blood pressure. Since the mechanism of NSAIDs’ 
blood pressure increase is related to PG inhibition, those who are taking high doses 
of antihypertensive medications might be more sensitive to the blood pressure 
increase associated with NSAIDs. For example, one study found that the effect of 
NSAIDs on the diuretic response of furosemide depends on the dose of the diuretics 
(144).   
Summary and Conclusions 
The first aim of the current research was to compare the effect of NSAIDs on 
blood pressure to acetaminophen in hypertensive patients. NSAIDs, compared to 
acetaminophen, were associated with a 2 mmHg increase in systolic blood pressure. 
The systolic blood pressure increase was 3 mmHg in a sub-sample of those who 
were prescribed ACE-I or CCB and 6 mmHg in those prescribed a beta-adrenergic 
blocker. No statistically significant change in blood pressure was associated with 
NSAIDs in patients prescribed diuretics or combinations of multiple antihypertensive 
medications. 
In the second aim of comparing the effect of various NSAIDs on blood 
pressure, ibuprofen was associated with a systolic blood pressure increase, 
compared to both naproxen and celecoxib, of 3 and 5 mmHg, respectively. 
Compared to naproxen, ibuprofen was associated with a systolic blood pressure 
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increase in those prescribed beta-adrenergic blockers by 6 mmHg. The third aim of 
this research was to examine changes in antihypertensive therapy after starting 
NSAIDs. No statistically significant changes in antihypertensive therapy were found 
in NSAIDs users. 
The increase in systolic blood pressure associated with NSAIDs is small 
when compared to acetaminophen and may not affect a physician’s decision to 
change antihypertensive therapy from one visit to another. However, ibuprofen was 
associated with a greater risk for systolic blood pressure increase by at least 20 
mmHg compared to naproxen. In the long term this change could be associated with 
significant comorbid consequences. For example, one study found that decreasing 
systolic blood pressure by just 2 mmHg lowers stroke mortality by 10% and ischemic 
heart disease mortality by 7% (24). For hypertensive patients who need NSAIDs, 
diuretics could be used to control blood pressure. Further studies are needed to 
confirm the results of this study.  
 
 111 
APPENDICES 
 
Appendix A. Tables  
Table 1 . Summary of Short-term Trials Examining the Effect of NSAIDs on Blood Pressure 
Main results 
Author Year NSAID/Dose Antihypertensive Sample size & population Design Duration SBP       
(mmHg) 
DBP or MAP* 
(mmHg) 
Lopez-
ovejero 
JA(11) 
1978 IND 200mg 
Chlorthalidone/ 
HCTZ or 
Propranolol 
N=26 with HTN --- 1 week --- IND ↑ 7.3 in Propranolol 
Koopmans 
PP (145) 1984 
IND 50mg, NAP 
250mg, or SUL 200mg HCTZ 50mg N=10 with HTN CO. 4 weeks ↔ ↔ 
Cinquegrani 
MP(73) 1986 
IND 200 mg or 
Placebo 
Intravenous 
hydralazine 
N=9. Healthy 
volunteers. R. DB. CO. 24 hours ↔ 
MAP: IND ↓ 4 
vs. placebo ↓9 
Koopmans 
PP(146) 1987 
IBU 400mg x3, DIC 
25mg x3, SUL 200mg 
x2 
HCTZ 50mg N=8 with HTN CO. 28 
weeks ↔ ↔ 
Radack 
KL(32) 1987 
IBU 400 mg x3, 
Acetaminophen 1 gm 
x3, or Placebo 
Controlled with at 
least 2 
antihypertensives 
N= 45 with HTN. R. DB. 3 wks 
IBU ↑ 6.8 
Placebo ↓ 
3.7 
IBU ↑ 5.3 
Placebo ↓ 1.1 
Davies 
JG(33) 1988 IBU 400 mg x4 
Propranolol or 
Bendrofluazide N=10 with HTN. R. DB. CO. 4 weeks ↔ ↔ 
Wright 
JT(34) 1989 
IBU 800 mg x4, or 
placebo HCTZ 
N=12 African 
American women 
with HTN. 
R. DB. CO. 8 days ↔ ↔ 
Klassen 
D(12) 1993 
IBU 800 mg x3 
NAP 375mg x2 HCTZ N=97 with HTN. R. DB. MC. 4 wks ↔ 
IBU ↑ 2.6 
NAP ↑ 1.8 
Polonia 
J(13) 1995 
IND 25 mg x3 
 
Enalapril or 
Nifedipine N=18 with HTN. R. CO. 1 week 
IND ↑ 6.8 in 
Enalapril 
group. 
IND ↑ 4.6 in 
Enalapril group. 
Houston 
MC(35) 1995 
IBU 400 mg x3. 
NAP 250 mg x2. 
Or placebo 
Verapamil. N=162 with HTN R. MC. DB. 3 weeks ↔ ↔ 
Klassen 
DK(36) 1995 
NAP 375 mg x2 
Or Placebo Nicardipine N=100 with HTN 
R. MC. DB 
 
4 weeks ↔ ↔ 
Gurwitz 
JH(37) 1996 
IBU 600 mg x3 
Or placebo HCTZ 
N=22, >60 yrs. 
With HTN. 
R. DB. CO. 
 
4 weeks IBU ↑ 5 ↔ 
Murray 
MD(72) 1997 
IBU 800 mg x3, PIR 
20mg, SUL 200 mg 
x2. 
None 
10 young, 14 
elderly, and 14 
elderly with renal 
insufficiency 
R, three-
way, CO. 36 days 
IBU vs. SUL 
↑ by 10 
IBU vs. SUL ↑ 
by 6.0 
Olsen 
ME(38) 1999 
IND 50 mg x2 
Or placebo Losartan N=10 with HTN. R. CB. CO. 1 week ↔ ↔ 
Morgan 
TO(39) 2000 
IND 50 mg x2 
Or placebo 
Amlodipine or 
Enalapril N=61 with HTN. DB. CO. 3 weeks 
IND ↑ 10 in 
Enalapril ↔ 
Whelton 
A(3) 2001 
CEL 200 mg or ROF 
25 mg Various 
N=810 ≥65yrs. 
With OA & HTN. 
R, DB. 
 
6 weeks ROF  ↑ 2.6 CEL ↓ 0.5 
 
↔ 
Fogari R(14) 2002 IND 50mg x3 or placebo 
Valsartan or 
Lisinopril 
N=128 with 
uncontrolled HTN 
(DBP>100 mmHg) 
R, CO, DB, 
MC. 
 
2 weeks 
IND ↑ in 
Lisinopril 
5.45 
↑ 2.12 in 
Valsartan 
IND ↑ in 
Lisinopril 3.22 
↑ in Valsartan 
1.87 
Whelton 
A(40) 2002 
CEL 200 mg or ROF 
25 mg 
ACE-I, B-B, CCB, 
Diuretic. 
N=1,092. > 65. 
With OA & HTN. R. DB. 6 weeks 
ROF  ↑ 3 
CEL ↓ 0.4 
 
↔ 
Dilger K(75) 2002 CEL 200 mg x2 DIC 75 mg x2 None 
N=24. 12 young 
and 12 elderly. R. DB. CO. 2 weeks 
 
↔ 
 
↔ 
Reitblat 
T(15) 2002 
ROF 25 mg 
Namebutone 2000 mg 
for 1 wk then 1000 mg 
ACE-I, B-B. N=20. With OA & HTN.  4 weeks ROF ↑ 15.7 ROF ↑ 8.5 
White 
WB(41) 2002 
CEL 200 mg x2 
Or placebo Lisinopril N=178. With HTN R. DB 4 weeks ↔ ↔ 
Palmer 
R(42) 2003 
IBU 800 mg x3, CEL 
200 mg x2, 
nabumetone 1000 mg 
x2, or placebo 
ACE-I N=385. With HTN 
 
R. MC. 
 
4 weeks ↔ ↔ 
Izhar M(16) 2004 CEL 200 mg Or DIC 75 mg x2 ACE-I 
N=25. African 
American & 
Hispanic with OA & 
HTN 
R. CO. 4 weeks CEL ↑ 4 DIC ↑ 4 
CEL ↑ 4 
DIC ↑ 2 
Sowers 
JR(43) 2005 
CEL 200 mg ROF 25 
mg 
NAP 500 mgx2 
Various N=404. With OA, HTN, and DM. R. DB. 
12 
weeks ROF ↑ 4 ROF ↑ 2 
Hinz B(76) 2006 
CEL 200 mg ROF 25 
mg x2 
DIC 75 mg x2 
None N=24. Healthy 
volunteers R. 8 days ↔ ↔ 
* DBP used unless otherwise stated. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: mean arterial pressure; CEL: Celecoxib; ROF: Rofecoxib; IBU: 
Ibuprofen, DIC: Diclofenac; NAP: Naproxen; SUL: Sulindac; IND: Indomethacin; HTN: Hypertension, R: Randomized. DB: double-blind. MC: Multi-center CO: Crossover; 
OA: Osteoarthritis; DM: Diabetes mellitus; ACE-I: Angiotensin converting enzyme inhibitor; B-B: Beta-blocker; CCB: Calcium channel blocker; HCTZ: 
Hydrochlorothiazide;  ↔ : No changes; ↑: Increase; ↓: Decrease. 
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Table 2 . Summary of Observational Studies Examining the Effect of NSAIDs on Blood 
Pressure 
First 
author Year Drug 
Sample size & 
population Design/Methods Main results 
Chrischilles 
EA(77) 1993 NSAIDs N=470. >65yrs.  
Cross-sectional. Community 
based. Medication use recorded 
from label. 
NSAIDs users were more likely to have 
SBP>140 mmHg (OR, 2.19; 95% CI, 1.33 - 
3.61).  
Johnson 
AG(25) 1993 NSAIDs 
N=2,805. >60yrs. 
In Australia. 
Cross-sectional. Community 
based. 
Risk of HTN was higher in NSAIDs users (OR, 
1.4; 95% CI, 1.1-1.7). 
Gurwitz 
JH(78) 1994 NSAIDs 
N=9,411 cases. New Jersey 
Medicaid. 
Case-control. Adjusted for: age, 
gender, race, nursing home 
residence, number of 
prescriptions, intensity of 
physician utilization, and days 
hospitalized. 
Risk of antihypertensive medications initiation 
was higher in NSAIDs users (OR, 1.66; 95% 
CI, 1.54-1.80). 
Curhan 
GC(26) 2002 
NSAIDs 
Aspirin 
Acetaminophen 
N=80,020. Women who 
participated in Nurses’ Health 
Study II. Age: 31-50yrs. No 
HTN. 
Prospective. Drug use & 
diagnosis of HTN were self-
reported. 
HTN risk increased in NSAIDs users (RR, 
1.86; 95% CI, 1.51-2.28) and acetaminophen 
users (RR, 2.0; 95% CI, 1.52-2.62) 
Dedier J(27) 2002 
NSAIDs 
Aspirin 
Acetaminophen 
N=51,630. Women who 
participated in Nurses’ Health 
Study. Age: 44-69yrs. No 
HTN. 
Prospective. Drug use & 
diagnosis of HTN were self-
reported. 
HTN risk increased in aspirin users (RR, 1.21; 
95% CI, 1.13-1.30), NSAIDs users (RR, 1.35; 
95% CI, 1.25-1.46), and acetaminophen users 
(RR, 1.20; 95% CI, 1.08-1.33). 
Kurth T(28) 2005 
NSAIDs 
Aspirin 
Acetaminophen 
N=8,229 healthy men 
physicians. Age 40-84 yrs. 
Prospective. Drug use & 
diagnosis of HTN were self-
reported. 
No significant increase in HTN risk in users of, 
NSAIDs, aspirin, or acetaminophen groups 
Cho J(70) 2003 ROF CEL N=109. 
Retrospective. Medical record 
review. Outcome: change in SBP 
after start of drugs.   
ROF increased SBP by 4.76 mmHg compared 
to baseline (P = 0.04). 
CEL did not affect BP. 
Nietert 
PJ(71) 2003 
ROF 
CEL N=960. >55yrs. With HTN 
Retrospective. Using electronic 
medical record. Followed for 6 
months. 
No change in BP (defined: SBP>20, or 
DBP>15), or new class of HTN drugs. 
Solomon 
DH(29) 2004 
ROF 
CEL 
N=3,915 cases. ≥65. 
Medicare. 
Case control. 90 days exposure 
to COX-2 before HTN diagnosis. 
Risk of HTN increased: 
ROF vs. CEL (OR, 1.6; 95% CI, 1.2-2.1) 
ROF vs. NSAIDs (OR, 1.4; 95% CI, 1.1-1.9) 
Fredy J(79) 2005 ROF CEL 
N=120. Native American from 
Indian Health Service. 
Medical record review for 
patients switched from CEL to 
ROF. Simple paired t-test. 
BP increased when switched from CEL to 
ROF: SBP: 2.9 mmHg (P = 0.02) & DBP: 1.5 
mmHg (P = 0.04) 
Yood 
MU(147) 2006 
NSAIDs 
ROF 
CEL 
N=23,562 cases. 
 
Case control. Cases: started 
antihypertensive therapy. Recent 
users: prescription within 60 
days. 
Risk of starting antihypertensive therapy in 
recent users: 
NSAIDs: (OR=1.6, 95% CI 1.5-1.7) 
COX-2 inhibitors: (OR=1.8, 95% CI 1.6-2.1) 
Wang J(30) 2007 NSAIDs CEL 
N=54,444. Non-
hypertensives. 
Retrospective cohort. Using 
electronic medical record. 
No changes in risk of HTN between CEL and 
NSAIDs (HR, 1.01; 95% CI, 0.86-1.19) 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; CEL: Celecoxib; ROF: Rofecoxib; HR: Hazard Ratio; HTN: Hypertension; OR: Odds Ratio; RR: Relative 
Risk. CI: Confidence Interval. 
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Table 3. Baseline Characteristics by Treatment Group 
Variable 
NSAIDs     
(n=2,181) 
N (%)* 
Acetaminophen 
(n=1,747) 
N (%)* 
Age (yrs) mean (SD) 55 (13) 60 (14) 
Gender:   
Female 1, 531 (70) 1,216 (70) 
Male 650 (30) 531 (30) 
Race:   
African American  1,264 (58) 1,093 (63) 
White 817 (37) 599 (34) 
Others 100 (5) 55 (3) 
Baseline Systolic blood pressure (mmHg) mean (SD) 139 (22) 141 (24) 
Diagnosis of:   
Osteoarthritis  487 (22) 397 (23) 
Rheumatoid Arthritis 65 (3) 44 (3) 
Renal insufficiency  60 (3) 145 (8) 
Cirrhosis with Ascites 8 (0.4) 10 (1) 
Systemic Lupus Erythematosus 19 (1) 10 (1) 
Diabetes  611 (28) 603 (35) 
Congestive Heart Failure 244 (11) 325 (19) 
Coronary Artery Disease or Past History of 
Myocardial Infarction 288 (13) 
333 (19) 
Stroke  166 (8) 213 (12) 
Arrhythmia 25 (1) 33 (2) 
Asthma or Chronic Obstructive Pulmonary Disease 380 (17) 338 (19) 
Medications:      
ACE-I or Angiotensin II blocker 779 (36) 758 (43) 
Beta - Blocker 399 (18) 296 (17) 
Calcium Channel Blocker 735 (34) 670 (38) 
Diuretic 952 (44) 841 (48) 
Other antihypertensive medications 157 (7) 203 (12) 
* Total N=3,928. N (%) unless indicated as mean (Standard Deviation). Because of rounding it may not add to 
100 %.  
ACE-I: Angiotensin converting enzyme inhibitor; 
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Table 4. Number of Eligible Subjects at Baseline by Study Aim and Hypothesis  
Aim Hypotheses Groups to compare (number of 
patients) 
H1: Compared to acetaminophen, NSAIDs cause a greater increase in systolic blood 
pressure in patients receiving beta-adrenergic antagonists, diuretics, ACE-I or 
angiotensin II receptor antagonists, or combination of these antihypertensive drugs. 
 
H2: NSAIDs are not associated with an increase in systolic blood pressure in patients 
receiving CCBs compared to acetaminophen. 
 
Aim 1 
To examine the association 
between NSAIDs and blood 
pressure compared to 
acetaminophen group in 
patients with hypertension. 
 
H3: Compared to acetaminophen, NSAIDs are not associated with an increase in systolic 
blood pressure in patients concomitantly receiving CCBs with drugs from other 
antihypertensive classes. 
 
NSAIDs (N=2,181) vs. Acetaminophen 
(N=1,747) 
 
Number of antihypertensive medications 
used in both NSAIDs and acetaminophen: 
ACE-I/AIIA: 1,324;   B-Blockers: 544 
CCB: 1,193;       Diuretics: 1,516 
H1: Ibuprofen, naproxen, and celecoxib do not differ in their propensity to increase 
systolic blood pressure. 
 
Celecoxib (N=143) vs. Ibuprofen 
(N=1,313) OR Naproxen (N=495) 
H2: As the dose of ibuprofen or naproxen increases, the systolic blood pressure 
increases. 
 
Dose: Ibuprofen (N=709), 
Naproxen (N=258) 
H3: In patients taking antihypertensive medications other than CCBs, the use of naproxen 
or ibuprofen is associated with an increase in systolic blood pressure. 
 
H4: In patients prescribed CCBs, naproxen or ibuprofen will not be associated with 
increases in systolic blood pressure. 
 
Aim 2 
To compare the effects of 
various NSAIDs on blood 
pressure in patients with 
hypertension. 
H5: In patients concomitantly receiving CCBs and antihypertensives from another class, 
naproxen or ibuprofen will not be associated with increases in systolic blood pressure. 
 
Ibuprofen (N=1,313) vs. Naproxen 
(N=495) 
Number of antihypertensive medications 
used in both ibuprofen and naproxen: 
ACE-I/AIIA: 528; B-Blockers:  244 
CCB: 515; Diuretics:  642 
H1: Compared to acetaminophen, NSAIDs increase the likelihood of adding a new 
antihypertensive medication or increasing the dose of a currently prescribed 
antihypertensive medication. 
NSAIDs (N=3,740) vs. Acetaminophen 
(N=3,109) Aim 3 
To examine the changes in 
antihypertensive therapy 
after starting NSAIDs. 
H2:  Ibuprofen, naproxen, and celecoxib do not differ in the need to add a new 
antihypertensive medication or increase the dose of the current antihypertensive 
medication. 
Celecoxib (N=193) vs. Ibuprofen 
(N=2,227) OR Naproxen (N=877) 
       ACE-I: Angiotensin converting enzyme inhibitor; AIIA: Angiotensin II antagonist; CCB: Calcium channel blocker; NSAIDs: Non-steroidal anti-inflammatory drugs;   
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Table 5. Type, Unit and Definition of Variables Included in the Statistical Models  
Variable Type Unit Definition 
Dependent:  
Systolic blood pressure 
 
Continuous 
 
mmHg 
 
The first systolic blood pressure value after the 
index date 
Changes in antihypertensive therapy Dichotomous --- Increase in dose or starting of another 
antihypertensive medication 
Independent: 
Age 
 
Continuous 
 
Years 
 
Age at index date  
Index drug Dichotomous --- NSAID or acetaminophen prescribed to patient 
Gender Dichotomous --- Gender  
Race  Categorical --- Race categorized as African American, white, 
and others.  
Medication adherence Categorical --- 
Calculated MPR = sum of the days’ supply 
obtained / total days from first prescription until 
last fill. 
Time to measurement of blood pressure Categorical Days  Number of days between index date and BP 
measurement 
Time prior index date Categorical Days Number of days from BP measurement until index date  
Year Categorical Years Year of index date 
Systolic Blood Pressure before Continuous mmHg  Last systolic blood pressure value before the index date 
Diagnosis of: 
   Rheumatoid Arthritis  
   Osteoarthritis  
   Arrhythmia 
   Myocardial Infarction 
   Coronary artery disease 
   Stroke  
   Congestive heart failure 
   Diabetes 
   Asthma 
   Chronic Obstructive Pulmonary Disease 
   Renal insufficiency  
Dichotomous --- Clinical diagnoses before index date 
Use of Medications: 
   ACE-I 
   Angiotensin II blocker 
   Beta- Blocker 
   CCB 
   Diuretic 
   Other antihypertensive medication    
   Venlafaxine 
   Oral contraceptive 
   Oral high dose glucocorticoid* 
Dichotomous --- The use of each drug or drug class before index date 
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; BP: Blood pressure.  
* High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
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Table 6. Baseline Characteristics by Treatment Group 
Variable 
NSAIDs     
(n=2,181) 
N (%)* 
Acetaminophen 
(n=1,747) 
N (%)* 
P Value ** 
Age (yrs) mean (SD) 55 (13) 60 (14) <.001 
Gender:    
Female 1, 531 (70) 1,216 (70) 0.687 
Male 650 (30) 531 (30) 0.687 
Race:    
African American  1,264 (58) 1,093 (63) 0.003 
White 817 (37) 599 (34) 0.040 
Others 100 (5) 55 (3) 0.007 
Baseline Systolic blood pressure (mmHg) mean (SD) 139 (22) 141 (24) 0.006 
Time from baseline SBP to index date: 
 
 
 
≤ 7 days  1,166 (53) 1,137 (65) <.001 
> 7 days and ≤ 30 days 306 (14) 179 (10) <.001 
> 30 days 709 (33) 431 (25) <.001 
Year of index date: 
 
 
 
1993 - 1996 1,084 (50) 1,017 (58) <.001 
1997-2002 857 (39) 706 (40) 0.477 
2002 - 2006 240 (11) 24 (1) <.001 
Diagnosis of: 
 
 
 
Osteoarthritis  487 (22) 397 (23) 0.768 
Rheumatoid Arthritis 65 (3) 44 (3) 0.381 
Renal insufficiency  60 (3) 145 (8) <.001 
Cirrhosis with Ascites 8 (0.4) 10 (1) 0.343 
Systemic Lupus Erythematosus 19 (1) 10 (1) 0.277 
Diabetes  611 (28) 603 (35) <.001 
Congestive Heart Failure 244 (11) 325 (19) <.001 
Coronary Artery Disease or Past History of 
Myocardial Infarction 288 (13) 
333 (19) 
<.001 
Stroke  166 (8) 213 (12) <.001 
Arrhythmia 25 (1) 33 (2) 0.055 
Asthma or Chronic Obstructive Pulmonary Disease 380 (17) 338 (19) 0.121 
Medications:       
ACE-I or Angiotensin II blocker 779 (36) 758 (43) <.001 
Beta - Blocker 399 (18) 296 (17) 0.270 
Calcium Channel Blocker 735 (34) 670 (38) 0.003 
Diuretic 952 (44) 841 (48) 0.005 
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Variable 
NSAIDs     
(n=2,181) 
N (%)* 
Acetaminophen 
(n=1,747) 
N (%)* 
P Value ** 
Other antihypertensive medications 157 (7) 203 (12) <.001 
Oral high dose glucocorticoid *** 17 (1) 24 (1) 0.068 
Oral Contraceptive 16 (1) 16 (1) 0.528 
Venlafaxine 17 (1) 6 (0.3) 0.075 
Adherence to antihypertensive medications:    
MPR > 80% 1,510 (69) 1,293 (74) 0.001 
MPR < 80% 287 (13) 209 (12) 0.262 
Not using antihypertensive medications (reference) 384 (18) 245 (14) 0.002 
Exposure to index drug:    
MPR > 80% 706 (32) 413 (24) <.001 
MPR 20-80 % 964 (44) 742 (43) 0.278 
MPR < 20% 511 (23) 592 (34) <.001 
Number of refills per month:    
< 1  1,056 (48) 1,110 (64) <.001 
≥ 1  1,125 (52) 637 (36) <.001 
* Total N=3,928. N (%) unless indicated as mean (Standard Deviation). Because of rounding it may not add to 
100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
*** High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure.  
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Table 7. Comparison of Covariate Balance between NSAIDs and Acetaminophen before and 
after Propensity Score Matching  
Variable Sample NSAIDs* Acetaminophen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) mean Unmatched 55 60 <.001 -42.0  
 Matched 56 57 0.119 -6.0 86% 
Gender:  
 
    
Female Unmatched 70 70 0.687 1.3  
 Matched 72 70 0.157 5.5 -323% 
Race:  
 
    
African American  Unmatched 58 63 0.003 -9.4  
 Matched 63 61 0.353 3.6 62% 
Others Unmatched 5 3 0.007 7.5  
 Matched 4 3 0.837 0.8 89% 
Baseline Systolic blood pressure 
(mmHg) mean Unmatched 139 141 0.006 -8.8  
 Matched 140 140 0.949 -0.2 97% 
Time from baseline SBP to index:       
≤ 7 days Unmatched 53 65 <.001 -23.8  
 Matched 62 61 0.596 2.0 91% 
> 7 days and ≤ 30 days Unmatched 14 10 <.001 11.6  
 Matched 10 11 0.380 -3.4 71% 
> 30 days Unmatched 33 25 <.001 17.4  
 Matched 28 28 0.975 0.1 99% 
Year of index date:       
1993 - 1996 Unmatched 50 58 <.001 -17.1  
 Matched 57 56 0.713 1.4 92% 
1997-2002 Unmatched 39 40 0.477 -2.3  
 Matched 41 42 0.741 -1.3 44% 
2002 - 2006 Unmatched 11 1 <.001 40.8  
 Matched 2 2 0.881 -0.6 99% 
Diagnosis of:       
Osteoarthritis  Unmatched 22 23 0.768 -0.9  
 Matched 21 22 0.295 -4.0 -327% 
Rheumatoid Arthritis Unmatched 3 3 0.381 2.8  
 Matched 3 3 0.819 0.9 69% 
Renal insufficiency  Unmatched 3 8 <.001 -24.5  
 Matched 4 4 0.922 0.4 98% 
Cirrhosis with Ascites Unmatched 0.4 1 0.343 -3.0  
 Matched 1 1 0.807 -0.9 69% 
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Variable Sample NSAIDs* Acetaminophen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Systemic Lupus 
Erythematosus 
Unmatched 1 1 0.277 3.5  
 Matched 1 1 0.465 -2.8 20% 
Diabetes  Unmatched 28 35 <.001 -14  
 Matched 28 31 0.124 -5.9 58% 
Congestive Heart Failure Unmatched 11 19 <.001 -20.9  
 Matched 14 14 0.651 -1.7 92% 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 13 19 <.001 -16.0  
 Matched 14 15 0.266 -4.3 73% 
Stroke  Unmatched 8 12 <.001 -15.4  
 Matched 9 9 0.784 -1.1 93% 
Arrhythmia Unmatched 1 2 0.055 -6.1  
 Matched 1 1 0.489 -2.7 56% 
Asthma or Chronic 
Obstructive Pulmonary Disease 
Unmatched 17 19 0.121 -5.0  
 Matched 18 19 0.420 -3.1 37% 
Medications:          
ACE-I or Angiotensin II 
blocker 
Unmatched 36 43 <.001 -15.7  
 Matched 37 38 0.594 -2.1 87% 
Beta- Blocker Unmatched 18 17 0.270 3.5  
 Matched 15 17 0.338 -3.7 -4% 
Calcium Channel Blocker Unmatched 34 38 0.003 -9.7  
 Matched 36 36 0.829 -0.8 91% 
Diuretic Unmatched 44 48 0.005 -9.0  
 Matched 46 45 0.921 0.4 96% 
Other BP medications Unmatched 7 12 <.001 -15.2  
 Matched 9 9 0.835 -0.8 95% 
Oral high dose 
glucocorticoid***  
Unmatched 1 1 0.068 -5.8  
 Matched 1 1 0.850 -0.7 87% 
Oral Contraceptives Unmatched 1 1 0.528 -2.0  
 Matched 1 1 0.998 0.0 100% 
Venlafaxine Unmatched 1 0.3 0.075 5.8  
 Matched 1 0.4 0.782 1.1 82% 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 69 74 <.001 -10.6  
 Matched 72 70 0.320 3.8 64% 
MPR < 80% Unmatched 13 12 0.262 3.6  
 Matched 12 13 0.159 -5.4 -51% 
 120 
Variable Sample NSAIDs* Acetaminophen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Not using antihypertensives 
(reference group) 
Unmatched 18 14 0.002 9.8  
 Matched 16 16 0.965 0.2 98% 
Exposure to index drug:       
MPR > 80% Unmatched 32 24 <.001 19.5  
 Matched 26 27 0.750 -1.2 94% 
MPR 20-80 % Unmatched 44 43 0.278 3.5  
 Matched 44 43 0.859 0.7 80% 
MPR < 20% Unmatched 23 34 <.001 -23.3  
 Matched 30 30 0.909 0.4 98% 
Number of refills per month:       
≥ 1 refills Unmatched 52 36 <.001 30.8  
 Matched 44 43 0.301 4.0 87% 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
*** High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=3,928 (2,181 NSAIDs and 1,747 
acetaminophen). Matched: only matched patients, N=2,680 (1,340 in each group). 
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Table 8. Difference in Systolic Blood Pressure between NSAIDs and Acetaminophen after 
Propensity Score Matching 
Sample Dependent Variable* 
Estimate of SBP  
(mmHg)** 
95% Confidence 
Interval P Value 
All Patients (n=2,680) First SBP 1.8 0.3 to 3.3 0.022 
 Average SBP 2.0 0.7 to 3.3 0.004 
ACE-I (n=768) First SBP 2.8 -0.2 to 5.8 0.067 
 Average SBP 2.8 0.2 to 5.4 0.035 
CCB (n=804) First SBP 2.5 -0.4 to 5.4 0.089 
 Average SBP 3.2 0.6 to 5.7 0.014 
BB (n=340) First SBP 6.3 1.7 to 10.8 0.007 
 Average SBP 5.5 1.4 to 9.6 0.008 
Diuretics (n=1,022) First SBP 0.2 -2.3 to 2.8 0.859 
 Average SBP 1.3 -0.8 to 3.4 0.236 
ACE-I: Angiotensin converting enzyme inhibitor; BB: Beta-blocker; CCB: Calcium channel blocker; SBP: Systolic 
blood pressure.  
* First SBP is the first systolic blood pressure measurement after the index date. Average SBP is the average of 
all systolic blood pressure measurements after the index date and prior to any changes in the antihypertensive 
therapy.  
** Estimate of SBP is the estimate difference between NSAIDs and acetaminophen after controlling for baseline 
SBP. A higher value means NSAIDs is associated with higher increase in systolic blood pressure compared to 
acetaminophen.  
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Table 9 . Difference in Systolic Blood Pressure between NSAIDs and Acetaminophen in 
Patients Using Combinations of Antihypertensive Medications after Propensity Score 
Matching 
Sample Dependent Variable* 
Estimate 
of SBP  
(mmHg)** 
95% 
Confidence 
Interval 
P Value 
CCB & ACE-I (n=202) First SBP 1.1 -5.6 to 7.8 0.748 
 Average SBP 3.1 -2.8 to 8.9 0.302 
CCB & BB (n=104) First SBP 4.0 -5.0 to 13.0 0.382 
 Average SBP 6.0 -2.0 to 14.1 0.141 
CCB & diuretics (n=328) First SBP 1.6 -3.3 to 6.5 0.517 
 Average SBP 3.5 -0.8 to 7.9 0.110 
ACE-I & BB (n=108) First SBP 7.5 -1.0 to 16.0 0.084 
 Average SBP 6.7 -1.1 to 14.5 0.091 
ACE-I & diuretics (n=366) First SBP 1.0 -3.4 to 5.5 0.647 
 Average SBP 1.2 -2.7 to 5.1 0.553 
BB & diuretics (n=156) First SBP 3.8 -3.9 to 11.5 0.330 
 Average SBP 4.2 -2.8 to 11.3 0.237 
CCB & ACE-I & diuretics (n=100) First SBP 1.5 -7.9 to 10.8 0.757 
 Average SBP 3.8 -4.9 to 12.4 0.391 
BB & ACE-I & diuretics (n=42) First SBP 6.8 -9.4 to 22.9 0.402 
 Average SBP 5.4 -10.3 to 21.1 0.487 
ACE-I: Angiotensin converting enzyme inhibitor; BB: Beta-blocker; CCB: Calcium channel blocker; SBP: 
Systolic blood pressure. 
* First SBP is the first systolic blood pressure measurement after the index date. Average SBP is the average 
of all systolic blood pressure measurements after the index date and prior to any changes in the 
antihypertensive therapy.  
** Estimate of SBP is the estimate difference between NSAIDs and acetaminophen after controlling for 
baseline SBP. A higher value means NSAIDs is associated with higher increase in systolic blood pressure 
compared to acetaminophen.  
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Table 10. Difference in Systolic Blood Pressure between NSAIDs and Acetaminophen in 
Sensitivity Analysis of Medication Possession Ratio and Refills per Month for Index Drug after 
Propensity Score Matching  
MPR categories 
(%)* 
Refills per 
month** 
Estimate of 
SBP  
(mmHg)*** 
Standard 
Error 
95% 
Confidence 
Interval 
P Value 
<20, 20 – 80, >80 ---- 1.8 0.783 0.3 to 3.3 0.02 
<10, 10 – 80, >80 ---- 1.8 0.783 0.3 to 3.3 0.02 
<30, 30 – 80, >80 ---- 1.8 0.784 0.3 to 3.4 0.02 
<20, 20 – 70, >70 ---- 1.8 0.783 0.3 to 3.3 0.02 
<20, 20 – 90, >90 ---- 1.8 0.783 0.2 to 3.3 0.02 
<10, 10 – 70, >70 ---- 1.8 0.783 0.3 to 3.3 0.02 
<10, 10 – 90, >90 ---- 1.8 0.783 0.2 to 3.3 0.02 
<30, 30 – 70, >70 ---- 1.8 0.784 0.3 to 3.4 0.02 
<30, 30 – 90, >90 ---- 1.8 0.785 0.3 to 3.3 0.02 
<20, 20 – 80, >80 ≥ 1, <1 1.7 0.783 0.2 to 3.3 0.03 
<20, 20 – 80, >80 ≥ .5, <.5 1.8 0.783 0.2 to 3.3 0.02 
<20, 20 – 80, >80 ≥ 2, <2 1.8 0.783 0.3 to 3.4 0.02 
<20, 20 – 80, >80 ≥ 3, <3 1.8 0.783 0.3 to 3.4 0.02 
N=2,680. MPR: Medication Possession Ratio; SBP: Systolic blood pressure.  
* MPR categories are the categorical variables for the MPR of the index drug. For example, in the first row 
patients were classified in the first MPR category if MPR for the index drug is less than 20%, in the second 
category if MPR is between 20% and 80%, and in the third if MPR is more than 80%.     
** Number of refills per month from the index date until the end of follow up period. A categorical variable was 
created to equal one if the number of refills satisfy the first value (i.e. ≥1, ≥ .5, ≥ 2, or ≥ 3) and equal zero if not. 
*** Estimate of SBP is the estimate difference between NSAIDs and acetaminophen after controlling for baseline 
SBP. A higher value means NSAIDs is associated with higher increase in systolic blood pressure compared to 
acetaminophen.  
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Table 11. Comparison of Covariate Balance between Naproxen and Ibuprofen before and after 
Propensity Score Matching  
Variable Sample Naproxen* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) age Unmatched 54 53 0.215 6.5  
 Matched 54 54 0.994 0.0 99 
Gender:  
 
    
Female Unmatched 73 68 0.053 10.3  
 Matched 72 73 0.853 -1.2 88 
Race:  
 
    
African American  Unmatched 51 62 <.001 -22.4  
 Matched 52 55 0.517 -4.2 81 
Others Unmatched 6 4 0.067 9.2  
 Matched 6 5 0.649 3.0 68 
Baseline Systolic blood pressure 
(mmHg) mean Unmatched 141 139 0.040 10.9  
 Matched 141 141 0.968 -0.3 98 
Time from baseline SBP to index:       
≤ 7 days Unmatched 57 51 0.023 12.0  
 Matched 57 58 0.851 -1.2 90 
> 7 days and ≤ 30 days Unmatched 13 14 0.678 -2.2  
 Matched 13 12 0.750 2.1 6 
> 30 days Unmatched 30 35 0.035 -11.2  
 Matched 30 30 0.977 -0.2 98 
Year of index date:       
1993 - 1996 Unmatched 41 58 <.001 -35.4  
 Matched 43 43 0.836 -1.3 96 
1997-2002 Unmatched 43 34 <.001 18.9  
 Matched 43 43 0.941 -0.5 97 
2002 - 2006 Unmatched 16 8 <.001 25.8  
 Matched 14 14 0.688 2.6 90 
Diagnosis of:       
Osteoarthritis  Unmatched 21 18 0.092 8.8  
 Matched 21 20 0.721 2.3 73 
Rheumatoid Arthritis Unmatched 2 2 0.989 -0.1  
 Matched 2 3 0.371 -5.8 -7938 
Renal insufficiency  Unmatched 1 3 0.032 -12.3  
 Matched 1 2 0.596 -3.5 72 
Cirrhosis with Ascites Unmatched 0.4 0.3 0.743 1.7  
 Matched 0.2 0.2 0.998 0.0 99 
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Variable Sample Naproxen* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Systemic Lupus Erythematosus Unmatched 0.4 0.5 0.728 -1.9  
 Matched 0.4 0.6 0.657 -2.9 -53 
Diabetes  Unmatched 29 26 0.165 7.3  
 Matched 29 29 0.919 -0.7 91 
Congestive Heart Failure Unmatched 10 10 0.987 -0.1  
 Matched 9 10 0.754 -2.0 -2269 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 14 12 0.194 6.7  
 Matched 13 15 0.412 -5.3 21 
Stroke  Unmatched 7 7 0.757 -1.6  
 Matched 7 6 0.576 3.6 -121 
Arrhythmia Unmatched 2 1 0.042 9.6  
 Matched 1 2 0.566 -3.7 61 
Asthma or Chronic Obstructive 
Pulmonary Disease 
Unmatched 16 16 0.975 -0.2  
 Matched 16 17 0.814 -1.5 -826 
Medications:          
ACE-I or Angiotensin II blocker Unmatched 38 33 0.055 10.0  
 Matched 37 40 0.375 -5.8 43 
Beta- Blocker Unmatched 20 16 0.066 9.5  
 Matched 19 21 0.436 -5.1 47 
Calcium Channel Blocker Unmatched 32 34 0.365 -4.8  
 Matched 32 35 0.359 -5.9 -25 
Diuretic Unmatched 40 42 0.438 -4.1  
 Matched 40 44 0.317 -6.5 -59 
Other BP medications Unmatched 5 8 0.034 -11.7  
 Matched 5 5 0.988 0.1 99 
Oral high dose 
glucocorticoid***  
Unmatched 0.8 0.8 0.951 -0.3  
 Matched 0.8 0.6 0.700 2.5 -662 
Oral Contraceptives Unmatched 0.6 0.8 0.727 -1.9  
 Matched 0.4 0.6 0.657 -2.9 -53 
Venlafaxine Unmatched 1 0.4 0.043 9.4  
 Matched 0.8 0.8 0.995 0.0 100 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 72 67 0.048 10.5  
 Matched 72 74 0.485 -4.5 57 
MPR < 80% Unmatched 12 14 0.261 -6.0  
 Matched 12 11 0.821 1.5 76 
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Variable Sample Naproxen* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Not using antihypertensives 
(reference group) 
Unmatched 16 19 0.166 -7.4  
 Matched 16 15 0.512 4.3 42 
Exposure to index drug:       
MPR > 80% Unmatched 41 21 <.001 44.1  
 Matched 39 36 0.430 5.1 88 
MPR 20-80 % Unmatched 45 48 0.234 -6.3  
 Matched 47 49 0.433 -5.1 19 
MPR < 20% Unmatched 14 31 <.001 -41.5  
 Matched 14 14 0.979 0.2 100 
Number of refills per month:       
≥ 1 refills Unmatched 52 54 0.419 -4.3  
 Matched 52 52 0.796 -1.7 61 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
*** High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=1,808 (1,313 ibuprofen and 495 
naproxen). Matched: only matched patients, N=944 (472 in each group).  
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Table 12. Difference in Systolic Blood Pressure between Naproxen and Ibuprofen after 
Propensity Score Matching  
Sample Dependent Variable* 
Estimate of SBP  
(mmHg)** 
95% Confidence 
Interval P Value 
All Patients (n=944) First SBP -2.0 -4.4 to 0.4 0.108 
 Average SBP -2.5 -4.6 to -0.5 0.015 
ACE-I (n=276) First SBP 0.7 -4.1 to 5.4 0.786 
 Average SBP -1.1 -5.3 to 3.0 0.593 
CCB (n=268) First SBP -2.3 -6.8 to 2.2 0.320 
 Average SBP -2.2 -6.1 to 1.7 0.261 
BB (n=130) First SBP -4.3 -10.6 to 2.0 0.187 
 Average SBP -5.9 -11.7 to -0.0 0.049 
Diuretics (n=340) First SBP -3.2 -7.6 to 1.2 0.158 
 Average SBP -3.3 -7.0 to 0.5 0.085 
ACE-I: Angiotensin converting enzyme inhibitor; BB: Beta-blocker; CCB: Calcium channel blocker; SBP: Systolic 
blood pressure. 
* First SBP is the first systolic blood pressure measurement after the index date. Average SBP is the average of 
all systolic blood pressure measurements after the index date and prior to any changes in the antihypertensive 
therapy.  
** Estimate of SBP is the estimate difference between naproxen and ibuprofen after controlling for baseline SBP. 
A positive value means naproxen is associated with higher increase in systolic blood pressure compared to 
ibuprofen. A negative value means ibuprofen is associated with higher increase in systolic blood pressure 
compared to naproxen.  
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Table 13. Difference in Systolic Blood Pressure between Naproxen and Ibuprofen in Patients 
Using Combinations of Antihypertensive Medications after Propensity Score Matching 
Sample Dependent Variable* 
Estimate of 
SBP  
(mmHg)** 
95% 
Confidence 
Interval 
P Value 
CCB & ACE-I (n=60) First SBP 0.4 -11.9 to 12.7 0.953 
 Average SBP -0.8 -11.7 to 10.1 0.886 
CCB & BB (n=34) First SBP -4.5 -18.8 to 9.7 0.521 
 Average SBP -4.4 -18.3 to 9.6 0.528 
CCB & diuretics (n=118) First SBP -3.2 -11.3 to 5.0 0.447 
 Average SBP -3.2 -9.5 to 3.2 0.326 
ACE-I & BB (n=40) First SBP -5.8 -19.1 to 7.5 0.379 
 Average SBP -10.1 -23.0 to 2.8 0.120 
ACE-I & diuretics (n=124) First SBP -3.3 -10.5 to 4.0 0.373 
 Average SBP -4.3 -11.0 to 2.5 0.216 
BB & diuretics (n=70) First SBP -7.0 -16.3 to 2.4 0.143 
 Average SBP -5.4 -14.0 to 3.2 0.217 
CCB & ACE-I & diuretics (n=28) First SBP -4.6 -22.9 to 13.8 0.610 
 Average SBP -0.5 -16.5 to 15.6 0.951 
BB & ACE-I & diuretics (n=22) First SBP -7.4 -29.2 to 14.4 0.483 
 Average SBP -8.9 -30.8 to 13.0 0.404 
ACE-I: Angiotensin converting enzyme inhibitor; BB: Beta-blocker; CCB: Calcium channel blocker; SBP: Systolic 
blood pressure. 
* First SBP is the first systolic blood pressure measurement after the index date. Average SBP is the average of 
all systolic blood pressure measurements after the index date and prior to any changes in the antihypertensive 
therapy.  
** Estimate of SBP is the estimate difference between naproxen and ibuprofen after controlling for baseline SBP. 
A positive value means naproxen is associated with higher increase in systolic blood pressure compared to 
ibuprofen. A negative value means ibuprofen is associated with higher increase in systolic blood pressure 
compared to naproxen.  
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Table 14. Comparison of Covariate Balance between Celecoxib and Ibuprofen before and after 
Propensity Score Matching  
Variable Sample Celecoxib* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) mean Unmatched 62 53 <.001 67.9  
 Matched 60 61 0.631 -6.4 91 
Gender:  
 
    
Female Unmatched 89 68 <.001 51.7  
 Matched 89 85 0.433 10.4 80 
Race:  
 
    
African American  Unmatched 48 62 0.001 -28.2  
 Matched 50 49 0.790 3.5 87 
Others Unmatched 5 4 0.624 4.1  
 Matched 4 3 0.701 5.1 -22.6 
Baseline Systolic blood pressure 
(mmHg) mean Unmatched 138 139 0.893 -1.2  
 Matched 140 137 0.247 15.4 -1171 
Time from baseline SBP to index:       
≤ 7 days Unmatched 50 51 0.850 -1.7  
 Matched 52 54 0.790 -3.5 -113 
> 7 days and ≤ 30 days Unmatched 20 14 0.047 16.4  
 Matched 20 17 0.605 6.9 58 
> 30 days Unmatched 29 35 0.200 -11.5  
 Matched 28 29 0.883 -1.9 83 
Year of index date:       
1993 - 2002 Unmatched 78 92 <.001 -41.9  
 Matched 84 80 0.388 11.5 73 
2002 - 2006 Unmatched 22 8 <.001 41.9  
 Matched 16 20 0.388 -11.5 73 
Diagnosis of:       
Osteoarthritis  Unmatched 58 18 <.001 91.1  
 Matched 50 38 0.061 25.0 73 
Rheumatoid Arthritis Unmatched 15 2 <.001 49.7  
 Matched 14 11 0.419 10.7 78 
Renal insufficiency  Unmatched 4 3 0.421 6.6  
 Matched 4 4 1.000 0.0 100 
Systemic Lupus Erythematosus Unmatched 6 0.5 <.001 29.6  
 Matched 3 3 1.000 0.0 100 
Diabetes  Unmatched 39 26 0.002 26.7  
 Matched 36 36 1.000 0.0 100 
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Variable Sample Celecoxib* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Congestive Heart Failure Unmatched 25 10 <.001 40.5  
 Matched 19 20 0.865 -2.2 94 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 25 12 <.001 34  
 Matched 17 22 0.313 -13.4 61 
Stroke  Unmatched 17 7 <.001 30.2  
 Matched 13 10 0.404 11.1 63 
Arrhythmia Unmatched 3 0.6 0.006 16.9  
 Matched 3 3 1.000 0.0 100 
Asthma or Chronic Obstructive 
Pulmonary Disease 
Unmatched 31 16 <.001 34.7  
 Matched 28 30 0.770 -3.9 89 
Medications:          
ACE-I or Angiotensin II blocker Unmatched 45 33 0.005 24.3  
 Matched 39 47 0.227 -16.1 34 
Beta- Blocker Unmatched 34 16 <.001 42.6  
 Matched 27 29 0.656 -5.9 86 
Calcium Channel Blocker Unmatched 36 34 0.685 3.6  
 Matched 34 39 0.407 -11.0 -210 
Diuretic Unmatched 65 42 <.001 47.8  
 Matched 62 63 0.981 -1.8 96 
Other BP medications Unmatched 6 8 0.548 -5.5  
 Matched 6 8 0.604 -6.9 -26 
Venlafaxine Unmatched 2 0.4 0.008 15.5  
 Matched 1 2 0.561 -7.7 50 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 83 67 <.001 38.4  
 Matched 83 86 0.581 -7.3 81 
MPR < 80% Unmatched 9 14 0.107 -15.2  
 Matched 7 10 0.472 -9.5 37 
Not using antihypertensives 
(reference group) 
Unmatched 8 19 <.001 -34.2  
 Matched 10 4 0.120 20.7 39 
Exposure to index drug:       
MPR > 80% Unmatched 76 21 <.001 130.9  
 Matched 73 71 0.768 3.9 97 
MPR 20-80 % Unmatched 22 48 <.001 -55.6  
 Matched 26 27 0.880 -2.0 96 
MPR < 20% Unmatched 1 31 <.001 -86.8  
 Matched 2 3 0.651 -6.0 93 
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Variable Sample Celecoxib* Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Number of refills per month:       
≥ 1 refills Unmatched 34 54 <.001 -41.7  
 Matched 37 36 0.890 1.8 96 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=1,456 (143 celecoxib and 1,313 
ibuprofen). Matched: only matched patients, N=226 (113 in each group).  
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Table 15 . Difference in Systolic Blood Pressure between Celecoxib and Ibuprofen or 
Naproxen after Propensity Score Matching  
Comparison Dependent Variable* 
Estimate of 
SBP(mmHg)** 
95% 
Confidence 
Interval 
P Value 
Celecoxib vs. Ibuprofen  
(n=226) 
First SBP -5.4 -10.8 to 0.0 0.051 
 Average 
SBP 
-5.2 -10.0 to -0.4 0.035 
Celecoxib vs. Naproxen  
(n=204) 
First SBP -0.3 -5.5 to 4.9 0.913 
 Average 
SBP 
-0.3 -5.1 to 4.5 0.897 
SBP: Systolic blood pressure. 
* First SBP is the first systolic blood pressure measurement after the index date. Average SBP is the average of 
all systolic blood pressure measurements after the index date and prior to any changes in the antihypertensive 
therapy.  
** Estimate of SBP is the estimate difference between celecoxib and the comparator drug (ibuprofen or 
naproxen) after controlling for baseline SBP. A positive value means celecoxib is associated with higher increase 
in systolic blood pressure compared to the comparator drug. A negative value means the comparator drug is 
associated with higher increase in systolic blood pressure compared to celecoxib. 
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Table 16. Comparison of Covariate Balance between Celecoxib and Naproxen before and after 
Propensity Score Matching  
Variable Sample Celecoxib* Naproxen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) mean Unmatched 62 54 <.001 60.6  
 Matched 60 59 0.805 3.5 94 
Gender:  
 
    
Female Unmatched 89 73 <.001 41.2  
 Matched 87 81 0.248 16.1 61 
Race:  
 
    
African American  Unmatched 48 51 0.547 -5.7  
 Matched 48 44 0.574 7.8 -37 
Others Unmatched 5 6 0.599 -5.1  
 Matched 6 7 0.774 -4.0 22 
Baseline Systolic blood pressure 
(mmHg) mean Unmatched 138 141 0.190 -12.5  
 Matched 139 141 0.387 -12.1 3 
Time from baseline SBP to index:       
≤ 7 days Unmatched 50 57 0.148 -13.7  
 Matched 52 52 1.000 0.0 100 
> 7 days and ≤ 30 days Unmatched 20 13 0.040 18.6  
 Matched 20 19 0.859 2.5 87 
> 30 days Unmatched 29 30 0.977 -0.3  
 Matched 28 29 0.877 -2.2 -691 
Year of index date:       
1993 - 2002 Unmatched 78 84 0.075 -16.3  
 Matched 80 78 0.729 4.8 70 
2002 - 2006 Unmatched 22 16 0.075 16.3  
 Matched 20 22 0.729 -4.8 70 
Diagnosis of:       
Osteoarthritis  Unmatched 58 21 <.001 81.0  
 Matched 49 43 0.399 11.8 85 
Rheumatoid Arthritis Unmatched 15 2 <.001 49.7  
 Matched 5 6 0.757 -4.3 91 
Renal insufficiency  Unmatched 4 1 0.021 18.4  
 Matched 1 3 0.313 -14.1 23 
Diabetes  Unmatched 39 29 0.037 19.4  
 Matched 37 36 0.885 2.0 90 
Congestive Heart Failure Unmatched 25 10 <.001 40.6  
 Matched 21 20 0.861 2.4 94 
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Variable Sample Celecoxib* Naproxen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 25 14 0.002 27.5  
 Matched 20 19 0.859 2.5 91 
Stroke  Unmatched 17 7 <.001 32  
 Matched 13 14 0.836 -2.9 91 
Arrhythmia Unmatched 3 2 0.360 8.0  
 Matched 3 4 0.701 -5.4 33 
Asthma or Chronic Obstructive 
Pulmonary Disease 
Unmatched 31 16 <.001 34.9  
 Matched 24 27 0.628 -6.8 81 
Medications:          
ACE-I or Angiotensin II blocker Unmatched 45 38 0.133 14.2  
 Matched 43 45 0.778 -3.9 72 
Beta- Blocker Unmatched 34 20 <.001 32.9  
 Matched 30 33 0.652 -6.3 81 
Calcium Channel Blocker Unmatched 36 32 0.375 8.3  
 Matched 35 40 0.470 -10.1 -21 
Diuretic Unmatched 65 40 <.001 52.1  
 Matched 57 56 0.888 2.0 96 
Other BP medications Unmatched 6 5 0.492 6.3  
 Matched 5 5 1.000 0.0 100 
Venlafaxine Unmatched 2 1 0.429 6.9  
 Matched 1 1 1.000 0.0 100 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 83 72 0.006 27.7  
 Matched 82 86 0.441 -10.7 61 
MPR < 80% Unmatched 9 12 0.346 -9.2  
 Matched 9 6 0.421 11.2 -22 
Not using antihypertensives 
(reference group) 
Unmatched 8 16 0.009 -26.8  
 Matched 9 8 0.800 3.5 87 
Exposure to index drug:       
MPR > 80% Unmatched 76 41 <.001 75  
 Matched 75 73 0.751 4.4 94 
MPR 20-80 % Unmatched 22 45 <.001 -48.9  
 Matched 24 26 0.745 -4.5 91 
MPR < 20% Unmatched 1 14 <.001 -47.9  
 Matched 2 2 1.000 0.0 100 
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Variable Sample Celecoxib* Naproxen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Number of refills per month:       
≥ 1 refills Unmatched 34 52 <.001 -37.3  
 Matched 34 39 0.468 -10.1 73 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=638 (143 celecoxib and 495 naproxen). 
Matched: only matched patients, N=204 (102 in each group).  
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Table 17. Comparison of Covariate Balance between NSAIDs and Acetaminophen before and 
after Propensity Score Matching  
Variable Sample NSAIDs*  Acetaminophen*  P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) mean Unmatched 55 60 <.001 -39.0  
 Matched 56 57 0.008 -7.5 81 
Gender:  
 
    
Female Unmatched 68 69 0.348 -2.3  
 Matched 69 68 0.362 2.6 -13 
Race:  
 
    
African American  Unmatched 59 64 <.001 -8.9  
 Matched 63 61 0.145 4.1 53 
Others Unmatched 4 3 0.162 3.4  
 Matched 3 4 0.588 -1.5 55 
Baseline Systolic blood pressure 
(mmHg) mean 
Unmatched 
141 
143 0.001 -3.5  
 Matched 141 142 0.223 -7.9 56 
Time from baseline SBP to index:       
≤ 7 days Unmatched 55 65 <.001 -21.6  
 Matched 61 61 0.931 -0.2 99 
> 7 days and ≤ 30 days Unmatched 12 9 <.001 9.4  
 Matched 8 10 0.101 -4.6 51 
> 30 days Unmatched 34 26 <.001 16.8  
 Matched 31 29 0.267 3.1 81 
Year of index date:       
1993 - 1996 Unmatched 52 59 <.001 -14.2  
 Matched 58 58 0.774 0.8 94 
1997-2002 Unmatched 35 39 <.001 -8.6  
 Matched 40 40 0.795 -0.7 91 
2002 - 2006 Unmatched 13 2 <.001 43.7  
 Matched 2 2 0.924 -0.3 99 
Diagnosis of:       
Osteoarthritis  Unmatched 23 24 0.070 -4.4  
 Matched 21 23 0.095 -4.7 -8 
Rheumatoid Arthritis Unmatched 3 3 0.562 1.4  
 Matched 2 2 0.588 -1.5 -9 
Renal insufficiency  Unmatched 3 9 <.001 -23.0  
 Matched 5 5 1.000 0.0 100 
Cirrhosis with Ascites Unmatched 0.4 0.5 0.479 -1.7  
 Matched 0.6 0.5 0.705 1.1 37 
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Variable Sample NSAIDs*  Acetaminophen*  P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Systemic Lupus Erythematosus Unmatched 0.7 0.5 0.185 3.2  
 Matched 0.5 0.5 1.000 0.0 100 
Diabetes  Unmatched 27 34 <.001 -15.1  
 Matched 28 30 0.052 -5.5 64 
Congestive Heart Failure Unmatched 11 19 <.001 -21.2  
 Matched 13 14 0.459 -2.1 90 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 13 18 <.001 -13.4  
 Matched 13 16 0.025 -6.4 52 
Stroke  Unmatched 8 11 <.001 -12.5  
 Matched 9 9 0.398 -2.4 81 
Arrhythmia Unmatched 1 2 0.019 -5.6  
 Matched 1 1 0.716 -1.0 82 
Asthma or Chronic Obstructive 
Pulmonary Disease 
Unmatched 17 18 0.049 -4.8  
 Matched 16 17 0.119 -4.4 7 
Medications:          
ACE-I or Angiotensin II blocker Unmatched 31 34 0.003 -7.2  
 Matched 30 31 0.157 -4.0 44 
Beta- Blocker Unmatched 16 14 0.030 5.3  
 Matched 13 14 0.231 -3.4 36 
Calcium Channel Blocker Unmatched 28 31 0.012 -6.1  
 Matched 29 29 0.553 -1.7 72 
Diuretic Unmatched 36 39 0.018 -5.7  
 Matched 37 37 0.860 -0.5 91 
Other BP medications Unmatched 7 10 <.001 -10.1  
 Matched 8 8 0.715 -1.0 90 
Oral high dose 
glucocorticoid***  
Unmatched 0.7 1 0.045 -4.8  
 Matched 0.9 0.9 0.881 -0.4 91 
Oral Contraceptives Unmatched 0.5 0.8 0.221 -2.9  
 Matched 0.7 0.8 0.869 -0.5 84 
Venlafaxine Unmatched 0.7 0.3 0.024 5.6  
 Matched 0.4 0.4 0.818 -0.7 88 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 68 74 <.001 -12.2  
 Matched 72 71 0.661 1.2 90 
MPR < 80% Unmatched 16 13 0.014 6.0  
 Matched 13 14 0.282 -3.0 49 
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Variable Sample NSAIDs*  Acetaminophen*  P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Not using antihypertensives 
(reference group) 
Unmatched 16 13 <.001 9.7  
 Matched 15 15 0.634 1.3 86 
Exposure to index drug:       
MPR > 80% Unmatched 38 29 <.001 18.5  
 Matched 32 32 1.000 0.0 100 
MPR 20-80 % Unmatched 43 43 0.507 -1.6  
 Matched 44 44 0.887 -0.4 75 
MPR < 20% Unmatched 20 28 <.001 -18.7  
 Matched 25 24 0.869 0.5 98 
Number of refills per month:       
≥ 1 refills Unmatched 57 46 <.001 21  
 Matched 53 51 0.148 4.1 80 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
*** High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=6,849 (3,740 NSAIDs and 3,109 
acetaminophen). Matched: only matched patients, N=4,988 (2,494 in each group). 
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Table 18. Comparison of Covariate Balance between Naproxen and Ibuprofen before and after 
Propensity Score Matching  
Variable Sample Naproxen*  Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Age (yrs) mean Unmatched 54 54 0.832 -0.9  
 Matched 54 54 0.600 -2.6 -206 
Gender:  
 
    
Female Unmatched 70 66 0.055 7.7  
 Matched 69 70 0.828 -1.1 86 
Race:  
 
    
African American  Unmatched 53 64 <.001 -22.5  
 Matched 55 54 0.726 1.7 92 
Others Unmatched 5 4 0.116 6.1  
 Matched 5 5 0.638 -2.3 61 
Baseline Systolic blood pressure 
(mmHg) mean 
Unmatched 
142 
141 0.450 3.0  
 Matched 142 141 0.801 1.3 59 
Time from baseline SBP to index:       
≤ 7 days Unmatched 59 52 <.001 15.1  
 Matched 58 60 0.511 -3.3 78 
> 7 days and ≤ 30 days Unmatched 10 12 0.157 -5.7  
 Matched 10 10 0.805 1.2 79 
> 30 days Unmatched 31 36 0.003 -12.1  
 Matched 32 30 0.590 2.7 78 
Year of index date:       
1993 - 1996 Unmatched 40 60 <.001 -41.2  
 Matched 43 46 0.229 -6.0 85 
1997-2002 Unmatched 41 31 <.001 21.2  
 Matched 42 39 0.155 7.1 67 
2002 - 2006 Unmatched 19 9 <.001 28.9  
 Matched 15 15 0.781 -1.4 95 
Diagnosis of:       
Osteoarthritis  Unmatched 21 19 0.240 4.6  
 Matched 19 21 0.453 -3.7 19 
Rheumatoid Arthritis Unmatched 2 2 0.702 -1.5  
 Matched 2 2 0.574 -2.8 -81 
Renal insufficiency  Unmatched 3 3 0.259 -4.6  
 Matched 3 3 0.874 -0.8 83 
Cirrhosis with Ascites Unmatched 0.6 0.4 0.556 2.4  
 Matched 0.6 0.6 1.000 0.0 100 
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Variable Sample Naproxen*  Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Systemic Lupus 
Erythematosus 
Unmatched 0.3 0.4 1.000 -1.7  
 Matched 0.4 0.9 0.205 -6.3 -271 
Diabetes  Unmatched 27 25 0.270 4.4  
 Matched 27 28 0.737 -1.7 62 
Congestive Heart Failure Unmatched 10 10 0.895 0.5  
 Matched 10 10 1.000 0.0 100 
Coronary Artery Disease or 
History of Myocardial Infarction 
Unmatched 14 13 0.486 2.8  
 Matched 13 14 0.515 -3.2 -18 
Stroke  Unmatched 6 8 0.279 -4.4  
 Matched 7 7 0.693 -2.0 55 
Arrhythmia Unmatched 1 1 0.793 1.0  
 Matched 1 1 0.807 1.2 -17 
Asthma or Chronic Obstructive 
Pulmonary Disease 
Unmatched 16 15 0.686 1.6  
 Matched 15 14 0.436 3.9 -142 
Medications:          
ACE-I or Angiotensin II 
blocker 
Unmatched 33 29 0.017 9.4  
 Matched 32 31 0.830 1.1 89 
Beta- Blocker Unmatched 16 14 0.140 5.8  
 Matched 16 17 0.313 -5.0 14 
Calcium Channel Blocker Unmatched 27 29 0.315 -4.0  
 Matched 28 28 1.000 0.0 100 
Diuretic Unmatched 34 35 0.511 -2.6  
 Matched 34 35 0.753 -1.6 40 
Other BP medications Unmatched 6 7 0.249 -4.7  
 Matched 6 6 1.000 0.0 100 
Oral high dose 
glucocorticoid***  
Unmatched 0.8 0.8 0.921 0.4  
 Matched 0.9 0.7 0.781 1.4 -251 
Oral Contraceptives Unmatched 0.5 0.6 0.792 -1.8  
 Matched 0.4 0.7 0.507 -5.0 -181 
Venlafaxine Unmatched 1 0.3 <.001 11.6  
 Matched 0.5 0.7 0.526 -3.2 73 
Adherence to antihypertensive 
medications: 
      
MPR > 80% Unmatched 70 66 0.069 7.3  
 Matched 70 70 0.744 -1.6 78 
MPR < 80% Unmatched 14 16 0.144 -5.9  
 Matched 14 15 0.478 -3.5 40 
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Variable Sample Naproxen*  Ibuprofen* P Value** Standardized Difference 
Bias 
Reduction 
(%) 
Not using antihypertensives 
(reference group) 
Unmatched 16 18 0.389 -3.5  
 Matched 17 15 0.272 5.5 -58 
Exposure to index drug:       
MPR > 80% Unmatched 48 27 <.001 45  
 Matched 44 43 0.841 1.0 98 
MPR 20-80 % Unmatched 40 48 <.001 -15.1  
 Matched 44 43 0.880 0.8 95 
MPR < 20% Unmatched 12 25 <.001 -36.3  
 Matched 13 13 0.604 -2.6 93 
Number of refills per month:       
≥ 1 refills Unmatched 60 58 0.276 4.4  
 Matched 59 59 0.960 0.3 94 
* % unless indicated as mean. Because of rounding it may not add to 100 %.  
** P-value of t-tests for continuous variables and chi-square tests for categorical variables.  
*** High dose was defined as ≥10mg for prednisonse, ≥50mg for cortisone, and ≥1.5 mg for dexamethasone. 
Standardized difference: 100 ( χ treated – χ control)/√ {(s2 treated + s2 control)/2}. A positive value means the treated 
group is higher in % (or mean) compared to the control group and negative value means the control is higher 
than the treated.    
Bias reduction (%) =1- {|Standardized difference
 matched| / | Standardized difference unmatched |} x 100. A positive 
value means bias is reduced by propensity score matching and negative means bias increased.  
ACE-I: Angiotensin converting enzyme inhibitor; MPR: Medication Possession Ratio; SBP: Systolic blood 
pressure. Unmatched: all patients before propensity score matching, N=3,104 (2,227 ibuprofen and 877 naproxen). 
Matched: only matched patients, N=1,610 (805 in each group).
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Appendix B. Categories of Antihypertensive Medications  
Category Sub-category Drug name 
chlorothiazide 
chlorthalidone 
hydrochlorothiazide 
polythiazide 
indapamide 
Thiazide 
  
  
  
  
  metolazone 
bumetanide 
furosemide 
Loop 
  
  torsemide 
amiloride K-sparing 
  triamterene 
eplerenone 
Diuretics 
  
  
  
  
  
  
  
  
  
  
  
  
  
Aldesterone blocker 
  spironolactone 
atenolol 
betaxolol 
bisoprolol 
metoprolol 
nadolol 
propranolol 
  
  
  
  
  
  
  timolol 
acebutolol 
penbutolol 
BB with ISA 
  
  pindolol 
carvedilol 
Beta blockers 
  
  
  
  
  
  
  
  
  
  
  
Combined alpha and BB 
  labetalol 
benazepril 
captopril 
enalapril 
fosinopril 
lisinopril 
moexipril 
perindopril 
quinapril 
ramipril 
Angiotensin converting 
enzyme inhibitors (ACE-I) 
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
 
  
 
 
 trandolapri 
candesartan 
eprosartan 
irbesartan 
losartan 
olmesartan 
telmisartan 
Angiotensin II antagonists 
  
  
  
  
  
  
  
  
  
  
  
  
  valsartan 
diltiazem  
verapamil 
amlodipine 
Calcium Channel Blockers 
(CCB) 
  
  
  
  
  
  
  
  
felodipine 
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Category Sub-category Drug name 
isradipine 
nicardipine 
nifedipine 
  
  
  
  
  
  
  
nisoldipine 
hydralazine Vasodilators 
  
  
  minoxidil 
doxazosin 
prazosin alpha 1 blcokers 
  
  terazosin 
clonidine 
methyldopa 
reserpine 
Other blood pressure 
medications 
  
  
  
  
  
  
Centrally acting drugs 
  
  
  guanfacine 
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